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SUMMARY
Adipose tissue is an important site of peripheral oestrogen 
biosynthesis. Since oestrogens have been implicated in the natural 
history of breast cancer and the human breast is invested in an 
abundance of adipose tissue the significance of such activity in 
breast adipose tissue was investigated.
A rapid, sensitive assay was developed for measuring both aromatase 
(oestrogen synthesis) and 17-beta hydroxysteroid dehydrogenase 
(17BHSD), - a pivotal enzyme in the interconversion of both
androgens and oestrogens.
Particulate fractions from adipose tissue were incubated with 
3
[1-beta H] androstenedione. Aromatase activity was monitored by 
3
the release of [ H] ^ 0 ,  17BHSD activity by measuring formation of
3
[ H] testosterone.
All samples investigated possessed both aromatase and 17BHSD 
activity. Aromatase activity in breast adipose tissue from the 
cancer patients was significantly higher (p< 0.0001) than in the 
benign group In contrast there was no difference between the 
groups in the levels of 17BHSD activity.
In 12 cancer patients, steroid metabolism was studied in the 
quadrants of the mastectomy specimens. Up to five-fold differences 
in levels of aromatase were observed between different quadrants 
but there was a significant trend towards higher aromatase activity 
in the Upper Outer Quadrant (p< 0.05). However a much more
12
significant distribution of activity was apparent in relation to 
tumour location, the main tumour mass always being located in the 
quadrant with the highest aromatase activity. In contrast 
quadrants with the lowest activity never contained tumour foci (p< 
0.001). The distribution of 17BHSD activity between the quadrants 
failed to reveal any link with the anatomical location of the 
quadrant or with tumour site.
Levels of 17BHSD activity were significantly higher around tumours 
>3cm in diameter compared with smaller tumours (p< 0.01). Activity 
was also higher in patients with nodal metastases compared with 
those who were node negative (p< 0.01). In patients who had 
received systemic therapy prior to surgery, higher levels of
activity were detected in patients who failed to respond to 
treatment than those who responded (p < 0.02). There was no
apparent relationship between aromatase activity and tumour size, 
nodal metastases or response to treatment.
The composition of triglyceride free fatty acids were also measured 
in twelve patients. A significant inverse correlation was found 
between the concentration of polyunsaturated fatty acids and 
adipose tissue 17BHSD activity, but not with aromatase activity. 
Local levels of polyunsaturated fatty acids may therefore be
involved in regulation of 17BHSD activity in adipose tissue.
These results suggest that local aromatase activity could be 
important in the evolution of breast cancers and that tumours with 
a poor prognosis are associated with elevated levels of 17BHSD in 
surrounding adipose tissue. Local steroid metabolism in breast
13
adipose tissue may therefore be a contributary factor in the 
natural history of breast cancer.
14
Chapter 1.
Breast Adipose tissue and breast cancer.
"One anatomical feature of the acinar and ductal epithelium of 
the breast seems to distinguish it from that of nearly all 
other glandular structures of the body - i.e. from puberty it 
is invested in an abundance of adipose tissue."
Beer & Billingham. 1978, ^
15
The aetiology and natural history of breast cancer have been the
97 155
subject of numerous investigations over the years ' , and
although much information has accrued on these subjects we are 
still a long way from full understanding of this complex and deadly 
disease. In the paper quoted above, the authors noted that little
if any attention has focussed on a fundamental feature of the
breast that makes it almost unique in comparison with all other 
glands in the body, and suggested that adipose tissue could be a 
significant factor in the aetiology of breast cancer.
In the following account the evidence that adipose tissue is 
involved in the normal and abnormal development of the mammary 
gland will first be reviewed before considering whether
quantitative or qualitative changes in breast adipose tissue could 
be linked with breast cancer.
In prepubertal animals and humans a pad of fibro-fatty tissue is
laid down in the mammary area and the mammary gland develops from
134
ingrowth of primitive ducts into this fat pad . This growth is 
stimulated by a combination of hormones in which oestrogen appears 
to be vital27'95'125.
The importance of the fat pad in this development was first
demonstrated in mice by Meyers in 1919 when he showed that duct
growth could be retarded if the size of the mammary fat pad was
104
reduced by food restriction . Hoshino took this a stage further 
by establishing that duct growth could be completely abolished if
the primitive ductal tissue was transplanted away from adipose
82,83 
tissue '
16
In fact mammary fat pads do not appear to differ from adipose
tissue elsewhere in the body in facilitating ductal growth since
transplanted glands are able to grow and develop normally even to
the extent of lactation in sites such as the retroauricular fat pad
82
and the peri-renal fat pad .
The extent of duct growth in the gland appears to be limited only
by the amount of adipose tissue available, and in this respect
there seems to be an interaction between the growing ducts and
44
adipose tissue to control the final density of mature ducts .
Although the duct system extends to the limits of the fat pad, only
a small proportion of the total fat pad volume.is occupied and
ducts do not touch each other except at points of origin. It
appears that around each duct there is a cylinder of adipose tissue
into which adjacent ducts do not enter. A similar duct free zone
exists at the border of the fat pad. These observations led
Faulkin to suggest that the spacing of the ducts in a normal
virginal gland is determined by a growth inhibiting system
44
imparted to the surrounding adipose tissue by the existing ducts .
From these established ducts, lobules composed of terminal ducts
and alveoli arise. In women this occurs some time after 
102 144
puberty ' , but in mice it is delayed until the first
44 144
pregnancy ' . The manner and extent of development
nevertheless seems to be similar in both species. The lobules 
arise from the pre-existing ducts to occupy the previously 
unoccupied interductal spaces and begin to replace the fatty 
stroma. If distinct duct growth-inhibition does exist there could
17
still be several possible explanations for this phenomenon:
1)Terminal ducts could be less sensitive to growth inhibition 
than larger ducts, and alveoli could be even less sensitive so that 
secreting alveoli can come into contact with one another;
2)Mammogenic hormones which stimulate lobule growth alter the 
growth-inhibiting mechanism; or 3)The inhibition only applies to 
ductal growth and only the smaller ducts can give rise to alveoli 
(i.e. alveoli cannot give rise to alveoli) then the number of 
alveoli is limited to those that can cover the terminal ducts and 
thus the whole mammary structure could be regulated by regulating 
the ducts.
Evidence that adipose tissue could be important in the development
of mammary tumours comes from further transplantation studies in
mice. Murine mammary tumours are thought to develop from
premalignant hyperplastic growths known as hyperplastic alveolar 
30
nodules (HAN) . The importance of adipose tissue in the growth
of these HAN and in their transformation into malignant tumours was
demonstrated when DeOme showed that 9 of 19 HAN grew and developed
into malignant tumours after transplantation into adipose tissue,
whereas very little growth occured in 60 HAN transplanted
subcutaneously (remote from adipose tissue) where only one tumour 
31
evolved . Interestingly no growth was observed in HAN
transplanted into intact mammary glands suggesting that HAN are
still susceptible to the growth regulating mechanisms in the normal 
44
gland . Such regulating mechanisms may also inhibit tumour
growth since it was also noted that transplanted tumours grew more
slowly in intact mammary glands than in adipose tissue cleared of
44
glandular elements .
18
In summary therefore, the evidence from mice indicates that adipose 
tissue is essential for normal mammary gland development, for the 
growth of hyperplastic nodules and for the development of tumours 
from these nodules. Adipose tissue associated with ducts in the 
normally developed gland however, seems to be able to inhibit 
further duct growth, retard the growth of transplanted hyperplastic 
nodules and impede the growth of transplanted tumours.
If similar mechanisms operate in humans, the normally developed
breast may have an optimum adipose/glandular tissue ratio which is
achieved at the completion of ductal growth and maintenance of this
ratio should inhibit growth of hyperplastic lesions. For
hyperplastic lesions to develop in a mature breast there must
therefore either be a relative or absolute increase in the amount
of adipose tissue present to permit or stimulate its growth, or a
loss of the growth-inhibitory process. If the latter occurs, the
mechanism for bypassing the inhibition must lie within the adipose
tissue surrounding the HAN rather than within the HAN itself since
the HAN loses its ability to grow when it is transplanted into an
44
intact mammary gland .
Comparison of mammary gland structure in different species in 
relation to their mammary cancer rates supports the suggestion that 
mammary adipose tissue is involved in tumour development.
38
Mammary cancer only seems to occur to any great extent in humans ,
41 41 140 86 144
cats , dogs , rats and mice . Ruminants such as cows and
goats, although bred for their large udder size appear to be
19
119 127
resistant to the disease ' . All of these species have
similar mammary gland structure and function at the level of ducts
and alveoli; the only substantial difference between them being the
amount of adipose tissue distributed in the gland. The mammary
gland of ruminants mainly consists of alveoli which closely abut
one another without extensive quantities of intervening tissue:
adipose tissue is found next to the skin and between the gland and
the abdominal wall but is not heavily interspersed between alveoli.
In contrast the species which are susceptible to mammary cancer all
119
have adipose tissue occupying interalveolar spaces . It is
interesting that these species are all monogastric and frequently
ingest considerable quantities of lipid resulting in intermittently
high blood lipid levels whereas ruminants never experience
significant elevation of blood lipids, largely due to their low fat
119
diet and complex digestive systems . (The importance of this
factor in producing mammary gland adiposity was demonstrated by
Stewart who induced adipose tissue deposition in a cow's udder by
150
an intravenous infusion of a lipid emulsion .) It is not only
ruminants however, which have reduced mammary adipose tissue;
rabbits, although monogastric, have very little mammary adipose
119 144
tissue and a low incidence of mammary cancer '
A further feature which distinguishes humans from other species is
that the human breast undergoes major anatomical development at the 
152
time of puberty . Breast enlargement is in fact the first
102
external sign of impending puberty m  girls , and the breast can
achieve its adult size before the first ovulation, which is usually
143 152
about a year or two after menarche ' . Much of this pubertal
134
breast growth is due to the development of the fatty stroma and
20
these tissues will predominate until the first pregnancy.
Since evolution has always operated to maximise fertility, in most 
species pregnancy usually follows immediately after puberty and the 
mammary gland becomes a functional organ soon after the 
commencement of an animal's reproductive life. It is interesting 
that man has chosen to suppress reproductive potential in only a 
few selected species: his wife, his domestic pets the cat and dog, 
and his laboratory animals - the species which now develop breast 
cancer. In his farm animals, on the other hand, fertility has 
always been at a premium in order to achieve maximum production of 
milk or offspring resulting in little if any latent period between 
mammary gland development and function.
Delay in initiating normal reproduction appears to be a critical 
factor in determining mammary cancer risk since it has now been
established that an early first pregnancy does appear to protect
v,,m ^98 4,86,112,144,157 , ' ^ .humans , and animals ' from subsequent tumour
development. A possible explanation for this phenomenon is that
the development of mammary epithelial cells for lactation is
thought to be a terminal process, i.e. once the cell achieves the
differentiated state of lactation it will never perform any other 
111 133
function ' . Undifferentiated "stem" cells in the gland are
thought to be the cells which are most likely to undergo malignant 
111 155
transformation ' , and an increase in the time between breast
development and functional differentiation of the gland will 
increase the period during which large numbers of undifferentiated 
cells are available for transformation. It may also be important 
that during this period there is a considerable amount of adipose
21
stroma present in the gland and while it is likely that the crucial 
effect of pregnancy is to induce differentiation of stem cells it 
could be significant that pregnancy and lactation result in a 
marked reduction in the proportion of adipose tissue in the 
breast‘d .
There are therefore a number of possible factors which may 
contribute to the varying incidence of mammary cancer between 
species but the evidence does support the theory that tumours 
develop in glands containing adipose tissue. What then is the 
evidence that an increase in the amount of adipose tissue is 
associated with increased risk?
38
The risk of developing mammary cancer increases in both humans 
41 139
and animals ' with increasing age. In Western countries the
32
increase in human breast cancer is almost linear with age , and
this correlates well with the proportion of adipose tissue within
the breast which also increases with age due to a gradual atrophy
126
of the glandular structures
Apart from ageing, the only other established condition which
increases the amount of adipose tissue in the breast is 
151
obesity . In mice Waxier has shown that obesity appears to
161
accelerate tumour development . It seems likely that similar
mechanisms could operate in humans since epidemiological 
34 35 170
studies ' ' have shown an increased incidence of breast cancer
in obese women with the difference being most marked in older 
women. Conversely there is also evidence that women who have
22
reduced amounts of body fat (athletes and swimmers) have a
64
decreased incidence of breast cancer . Finally, if adipose
tissue does favour the growth of tumours then one would expect
obese women or women with predominantly fatty breasts to have more
rapidly growing tumours. While tumour growth rates have not been
33 39 40
studied in relation to breast type the reports ' ' of a poorer
prognosis in obese breast cancer patients is consistent with more 
rapid tumour growth in these women.
Precise measurement of the amount of adipose tissue in breasts is
extremely difficult, if not impossible in vivo, and it is not
surprising therefore that comparison of the amounts of adipose
tissue present in cancerous breasts and controls have not been
reported. Winder, however, reports that Japanese women with
breast cancer have larger breasts with more subcutaneous fat than
169
women without the disease . Although larger breasts might be
expected to contain more adipose tissue, breast volume is
apparently not a reliable guide to the amount of fat in the breast
and gives no indication of the likely adipose/glandular tissue
151
ratio within the organ
The fact that a difference was found in Japanese women is
interesting since the lowest incidence of human breast cancer is
38
found in indigenous Japanese women . This incidence has however
been rising in recent years and a marked increase is seen in
24 42
Japanese women who have emigrated to the West '
1 q t  “j n  /“
Sasano ' has suggested that this could be linked to an 
increase in the amount of breast adipose tissue: In an analysis of
23
breasts removed at autopsy from a series of indigenous Japanese 
women and Japanese immigrants to Hawaii, the incidence of 
hyperplastic breast disease was 51.4% in the Hawaiian Nissei 
compared to only 18.7% in the indigenous population, with a 
positive correlation between the presence of hyperplastic disease 
and the amount of breast fat. The Hawaiian women had 
significantly larger breasts than the native Japanese which was 
entirely due to an increase in adipose tissue.
The predominance of adipose tissue in cancerous breasts has been
3
demonstrated by Anastassiades who analysed the distribution of 
solid and fatty tissues in a series of 112 cancerous breasts and 
found that 94(86%) of the breasts were entirely or predominantly 
fatty. Even the 18 cases with a reasonable amount of 
"solid" tissues still contained considerable quantities of adipose 
tissue.
The above evidence therefore supports the theory that adipose 
tissue is a factor in the development of hyperplastic breast 
disease and breast cancer but the precise role that it plays has 
yet to be determined. Since adipose tissue is vital for the 
normal growth of the mammary gland it is reasonable to suggest that 
it produces or processes growth-stimulating factors which act 
locally on epithelial cells. Moreover since cell multiplication 
is an essential step in the development of premalignant or 
malignant lesions it seems likely that the same mechanism could act 
as a promoter of tumour development.
Although the precise nature of growth-stimulating factors which act
24
on the breast is still the subject of much debate, it is accepted
that an essential requirement for normal development is a suitable
27 95 137
hormonal environment ' ' . Various combinations of the
hormones oestrogen, progesterone, prolactin, growth hormone and
corticosteroids are needed to produce optimum growth of ducts,
development of lobules and alveoli, and differentiation for 
6 95 125 137
lactation ' ' ' Although with such a complex inter-play of
hormones it is difficult to single out one factor, current dogma
favours oestrogen as the key hormone in the growth and development
95 137
of the normal ducts ' . In keeping with this, it has been
shown that if breast tissue is maintained in organ culture, as
gland explants, oestrogen is capable of stimulating nucleic acid
158
synthesis in breast epithelial cells . In recent cell culture
experiments however, Haslam has demonstrated that oestrogen is only
capable of stimulating epithelial cell growth when stromal
fibroblasts are present, either in large numbers or in direct
74
contact with the epithelial cells . When isolated epithelial 
cells and fibroblasts were cultured together, differences occured 
in the morphology of both cell types, suggesting that cell-cell 
communication or another interactive phenomenon was taking place 
and that it was bi-directional. Furthermore as epithelial cells 
became confluent in co-culture, the presence of live fibroblasts 
appeared to inhibit epithelial cell proliferation - provided there 
was no added oestrogen.
Such observations are interesting in view of the relationship which 
has already been outlined between the mammary fat pad and the 
developing gland. The suggestion that local levels of oestrogen 
could be the factor that determines whether stromal cells will
25
stimulate or inhibit the growth of epithelial cells is particularly
intriguing since excessive oestrogenic stimulation of the mammary
gland has been suggested as a key factor in mammary tumour 
90
development . The whole issue is now also of particular 
relevance to the role of adipose tissue within the gland since it 
has now been established that adipose tissue is capable of 
synthesizing oestrogens locally from circulating adrenal 
androgens2'10'29'37'53'55'57'65'115'121'138'147'148'171.
Although it is only in the past few years that attention has
focussed on the possible significance of oestrogen biosynthesis in
adipose tissue, compelling evidence in support of its role was
provided, quite unintentionally, by the experiments of Waxier in
the 1950!s161 163. Gold thioglucose, which destroys the satiety
centre of the hypothalamus, was administered to mice to induce
obesity. Mammary tumours developed earlier in the obese mice than
161
in non-obese controls . A group of the obese animals were then
given a reducing diet. Obese animals which were slimmed down to the
same weight as controls then took much longer than the controls to
1 fi?
develop mammary tumours . No satisfactory explanation was 
offered for this unexpected finding.
Some years later, however, additional studies using this
experimental model revealed that the animals which became .obese
also became infertile and remained infertile even when slimmed
1
down to their original weight . Investigation of these animals 
revealed that they all had atrophic ovaries which presumably 
resulted from coincidental damage to the hypothalamic centre which 
normally releases gonadotrophins - a rather unusual form of
26
hormonal ablation. Since ovarian ablation is known to markedly
41 45 92 139
reduce the incidence of mammary cancer ' ' ' - the lack of
ovarian function in these animals presumably accounts for the fall 
in tumour incidence in the "slimmed" animals.
Despite the lack of functioning ovaries in the obese animals, 
vaginal smears indicated that chronic oestrogenic stimulation was 
occuring. Waxier at that time did not speculate as to the likely 
source of this oestrogen but the fact that there was no evidence of 
oestrogenic stimulation in the "slimmed" animals suggests that it 
was being produced in adipose tissue. The implication from 
these experiments that adipose tissue is able to produce 
sufficient oestrogen to enhance tumour growth in the absence of 
functioning ovaries lends strong support to the theory that local 
oestrogen production could be an important factor in the 
development of mammary tumours.
Although these experiments were performed in the 1950's it was not
until 1972 that definitive proof of the ability of adipose tissue
138
to produce oestrogens appeared . This early study detected the 
formation of oestrone from the androgen, androstenedione. 
This, and the convertion of testosterone to oestradiol have
now been confirmed in adipose tissue from a number of
..2,10,29,37,53,55,57,65,115,121,147,148,171sites ' ' ' ' ' ' ' ' ’ r ' ' . The reaction
involves the formation of an aromatic ring in the A-ring of the
steroid nucleus; the process is therefore known as aromatisation
and the enzymes which perform the reaction are known as 
49
aromatase(s)
27
Peripheral (extra-gonadal) aromatase activity has also been shown
12 94 65 149 141
to reside in skin , muscle , liver ' , hair-follicles , and
brain‘d I n  these tissues and in adipose tissue, activity
2 29 147
is located predominantly in the stromal cells ' ' , and while it
is generally accepted that peripheral aromatase is the major source
69
of oestrogen production in post-menopausal women little is known 
about the factors which influence levels of activity in vivo.
Levels of activity vary between individuals and also between
*. u ^ -i. 37,53,55,57,65,115,121,138different body sites ' ' ' ' . Possibly as a
result of this variation there is little consensus about the
relationship of activity to such factors as menopausal status, age
and obesity.
96
MacDonald was unable to demonstrate any difference in activity in
adipose tissue from ovulatory or anovulatory young women, but
suggested that higher activity was present in postmenopausal women.
28 57
This is in agreement with the findings of Cleland , Forney and 
76
Hemsell who suggest that activity increases with age. 
37
Deslyspere however, has recently published results indicating
that activity is greater in premenopausal women, and other studies
have failed to find any correlation between activity and a g e ^ ' " ^ .  
43
Edman appears to be the only one who has found that activity per
unit mass of adipose tissue increases with obesity, but there is
little doubt that total peripheral aromatase is increased in obese
89 173
subjects compared with controls '
Adipose tissue can also hydrolyse oestrone sulphate to produce free 
72
oestrone and can interconvert oestrone and oestradiol via the
10 11 37 52 55
17-beta-hydroxysteroid oxidoreductase pathway ' ' ' ' This
28
activity could be important since oestradiol is biologically much
c n  *7 1 T O
more active than either oestrone or its sulphate ' '
The biological significance of oestrogen biosynthesis in adipose
tissue can be inferred from the association of obesity with
oestrogenic effects. These effects are apparent from an early 
62 63
age: Frisch ' has demonstrated that the onset of menarche,
22
(which is determined by oestrogen levels ), is related to body
weight and that the weight/height ratio appears to be the critical
172
factor. This was confirmed by Zacharias who also showed that
menarche occurs significantly earlier in obese girls. This
acceleration of maturation by obesity in girls was again noted in
160
the Bogalusa Heart Study where it contrasted with the effect on 
boys. Obese boys were prone to develop gynaecomastia and when 
this occurred it was associated with a delay in male sexual 
maturation. Both of these features would be consistent with an 
oestrogenic effect of obesity. Such an antagonistic effect of 
obesity on male sexual maturation has also been observed in rats: 
those animals with the lowest percentage of body fat having 
significantly larger prostates, seminal vesicles and testes than 
fatter controls .
Although these studies did not involve correlation of levels of
oestrogen with obesity, other investigations have established this 
36
link. DeWaard has shown that in obese postmenopausal women 
there is a significant link between levels of oestrone excretion 
and obesity and that this correlation disappears after weight loss. 
He was unable to demonstrate any effect on levels of oestradiol, 
probably because the major circulating oestrogens in postmenopausal
29
118
women are oestrone and its sulphate. O'Dea however, has 
reported decreased serum oestradiol levels in a group of women who 
lost a greater amount of weight.
89
Kirschner reported similar findings in both men and women and
noted that in obesity there is increased production of
androstenedione which contributes to the elevated oestrogen
production. In addition he and o t h e r s ^ h a v e  noted that
obesity is associated with decreased levels of
sex-hormone-binding-globulin which results in higher levels of
free (unbound) oestrogen in plasma. (Unbound oestrogens are
believed to be the biologically active mediators of hormone 
5 146
action ' ). Not only is adipose tissue a significant source of
oestrogen production, it is also an important site for the uptake
of oestrogens from p l a s m a ^ ' r e s u l t i n g  in local
concentrations of oestrogen which may be up to fifteen times higher 
37
than in plasma .
Evidence that such altered sex-hormone metabolism in obesity could
have an effect on tumour biology comes from the well-documented
association of obesity with tumours of the endometrium, prostate 
89
and breast - organs which are normally targets for hormone
action. Furthermore, DeWaard has found that oestrogen-receptor
positive breast cancers are more common in obese patients than in 
33
leaner controls .
In summary therefore there is evidence to support the theory that 
adipose tissue plays a vital role in the normal development of the 
mammary gland and that the presence of excess adipose tissue is
30
associated with the development of hyperplastic lesions and 
malignant tumours. Recent evidence suggests that the stroma may 
interact with epithelial cells to stimulate or inhibit growth and 
that a crucial factor in determining the nature of this interaction 
could be levels of oestrogen. Since adipose tissue is capable of 
synthesizing oestrogen locally within the breast it is not 
unreasonable to suggest that an increase in oestrogen biosynthesis 
within the breast could favour the development of breast cancer.
Despite the above evidence very few studies have been performed on
breast adipose tissue to establish if there are differences in
oestrogen biosynthesis between cancer cases and controls. Nimrod 
115
and Ryan compared aromatase activity m  adipose tissue from five
cancerous breasts with two controls and concluded that they had
similar activity - but one of their control samples came from the
121
uninvolved breast of a cancer patient. Perel & Killinger
compared five cancer cases with four controls and concluded that-
there was no statistically significant difference between the 
groups - although they did find the highest levels of activity in 
the cancerous breasts. Beranek^ compared 17 cancer cases with 16 
controls and also concluded that, there was no statistically 
significant difference in levels of activity between the two
groups, but he was only able to detect activity in 50% of his
control group whereas activity was detected in 82% of the cancer 
cases, suggesting that with a more sensitive assay a significant 
difference might have emerged.
The aim of this project was therefore to establish a sensitive 
assay for measuring oestrogen biosynthesis in breast adipose tissue
31
in order to undertake detailed investigation of levels of activity 
in cancerous and non-cancerous breasts.
32
Chapter 2.
Development of aromatase assay.
33
Introduction
The conversion of androgens to oestrogens is catalysed by the
aromatase complex and involves the loss of the angular methyl
group and cis elimination of the 1-beta and 2-beta hydrogens from
the steroid nucleus of the precursor so that the A ring becomes 
49
aromatic . Androstenedione and testosterone are thus converted 
to oestrone and oestradiol respectively as is shown in Figure 2:1.
Conventional assays for aromatisation use androgens labeled with 
tritium at a stable position in the steroid nucleus (eg Cy which
is rarely metabolised) and involve the tracing of the label into
, j , 10,109,115,138 . ,,
oestrogen products . This requires . the
chromatographic separation of oestrogens from other steroid
components which are likely to be radioactively labeled i.e. the
unmetabolised androgen precursor and other androgen products.
Such purifications can be both difficult and time consuming.
Since it is planned to conduct a large survey of enzyme activities
in breast adipose tissue, a more rapid aromatase assay is
desirable.
Such a rapid assay has been described which uses androgen
substrates labeled in the 1-beta or 1-beta & 2-beta positions and
measure the release of tritium as water or aqueous products during
the formation of the aromatic A r i n g ^ ' ^ ' ' ^ .  Most of the
studies using such assays have either been on very active tissue
156
preparations such as placenta or have used placental
preparations to validate the assay before applying it to less 
active tissues such as adipose tissue stromal
34
OESTROGEN BIOSYNTHESIS
0
A k androstenedione
11
OH
testosterone
HO
oestrone
1 1
OH
HO
oestradiol
Figure 2:1. Oestrogen Biosynthesis.
The and positions on the steroids are indicated
in 2,28,29,103,147,148 ,,
cells ' ' . Since all studies to date
on adipose tissue have found comparatively low
aromatase activity (less than 1% convertion of
a ^ ^  2,10,29,37,53,55,57,65,115,121,138,147,148v .. . .. . nandrogen ' ' ' ' ' ), it is critical
to establish the sensitivity and reproducibility of the "tritium
release" assay in adipose tissue initially before embarking on a
large scale study. The immediate objectives of this project were
therefore to establish whether the rapid "tritium release" assay
will accurately measure the extent of oestrogen biosynthesis in
adipose tissue and to define the form of tissue preparation and
assay conditions which will produce optimum results.
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The "product identification" assay against which the "tritium 
release" assay will be compared is described below (page 40). This 
assay has been in use for a number of years and its accuracy and 
reliability are well established^®'
A variety of tissue preparations have been used to measure adipose
tissue aromatase activity in vitro. These include tissue
57 57 13 53 2 121
slices , minces , cell suspensions ' or cultures ' ,
, . 10,13,138 , . i _ _ _ _ , 13,57,115
homogenates ' ' and various subcellular fractions ' '
Opinions differ on which is the most suitable. The method
115
described by Nimrod & Ryan utilised the soluble extract of 
tissue homogenates and has subsequently been used successfully by a 
number of groups. This method was therefore adopted for the initial 
experiments.
A variety of modifications have been suggested for the "tritium
61
release" assay which was originally described by Frieden et al .
35
A modification of this method has been used with success in The 
Department of Clinical Surgery of Edinburgh University for studies 
on placental aromatase. This method (page 39) was therefore
adopted for the initial comparisons and modified as the experiments 
progressed.
A large number of experiments were performed in the initial stages 
of this project in order to establish an accurate, reproducible 
assay. Only the most relevant of the experiments are included in 
the following sections. As improvements were made they were
incorporated into the method for subsequent experiments. To avoid 
repetition of the full assay procedure after each modification, 
details will be given only of the particular feature of the assay 
which is under investigation.
Adipose tissue was used in the majority of the experiments. In some 
of the preliminary experiments ovarian microsomes were used since 
they usually exhibit higher aromatase activity than adipose tissue 
and therefore require shorter incubation times.
Experiment 1.
Comparison of the "product identification" and "tritium release" 
assays for measuring aromatase activity in breast adipose tissue.
Materials & Methods
Chemicals:
3 3
1-beta,2-beta H androstenedione (56 Ci/mmol) and 1,2,6,7 H
androstenedione (83 Ci/mmol) were obtained from New England
Nuclear. Prior to use they were purified by silica gel thin layer
chromatography in chloroform:acetone (185:15 v/v).
Radio-inert androstenedione, glucose 6 phosphate dehydrogenase 
(Type XI), NAD (grade V), glucose 6 phosphate (disodium salt), 
ATP (Disodi'um salt), NADP (Monosodium salt), nicotinamide and 
activated charcoal were obtained from Sigma Chemical Co Ltd, 
Poole, Dorset. NE260 Scintillant was obtained from Nuclear 
Enterprises Ltd, Edinburgh; Scintol 7 from Koch-Light Ltd, 
Haverhill, Suffolk; and bovine serum albumin from Armour
Pharmaceuticals, Eastbourne. Other chemicals and solvents were 
obtained from BDH Chemicals Ltd, Poole.
Patients:
Adipose tissue was obtained from breast cancer patients treated 
either by mastectomy or wide local excision.
Tissues:
Breast adipose tissue was obtained from the surgical specimens 
immediately after excision and transferred to the laboratory on 
ice. All procedures were then performed at 4°C unless otherwise 
stated. Samples were rinsed in 0.1M phosphate buffer (pH
7.4) before carefully dissecting adipose tissue free from any 
obvious breast parenchyma or fibrous tissue.
Preparation of Soluble Fraction of Adipose Tissue:
115
Tissue was processed according to the method of Nimrod & Ryan 
Two grams of adipose tissue were homogenised by hand in a
glass-to-glass homogenizer with 2 ml of 0 .1M phosphate buffer 
(pH 7.4) containing nicotinamide (lOmM) and Magnesium Chloride 
(5mM) then centrifuged at 800g for 5 minutes. The resultant 
supernatant (soluble fraction) was separated from the upper layer 
of solid lipid and the lower layer of cell debris using a pasteur 
pipette.
Assays:
2 grams of adipose tissue obtained from patient 1 was used to
prepare 2ml of "soluble extract". 0.5ml was then incubated 
according to the "tritium release" method outlined below, 1ml was 
incubated in parallel by the "product identification" method
(below).
Tritium Release Assay
Cofactors [glucose 6-phosphate (lOmM), glucose 6-phosphate 
dehydrogenase (2u/ml) and 2 mM each of NAD, NADP and ATP] and
"3
substrate [100 nM 1-beta,2-beta H androstenedione (2.5 uCi) 2.5 x
6 o
10 dpm) ] were pre-incubated for 15 minutes at 37 C in a total
volume of 500 ul phosphate buffer (O.lM, pH 7.4). Enzyme
reactions were started by addition of the soluble fraction
(500 ul) to substrate and co-factors. A blank incubation was
also set up using 500 ul of bovine serum albumin (2.0 mg/ml) in
place of the soluble fraction. The incubation was then performed
over 3 hours at 37°C with continuous shaking. Aliquots (500
ul) of the reaction mixture were removed into 1.625% charcoal
solution (800 ul) immediately and after 3 hours, mixed, and
allowed to stand on ice for a further 20 minutes with occasional
further mixing to adsorb the steroids onto the charcoal. The
charcoal was then precipitated by centrifugation at 2,000 g
for 15 minutes and the supernatant decanted into a glass
counting vial containing NE 260 Scintillation fluid (10 ml).
Radioactivity was measured on a Packard Tri-Carb Liquid
Scintillation spectrometer. Counts obtained in the blank
incubations were subtracted from the counts in the tissue
incubation to determine the amount of tritium released during
aromatisation.
The % conversion of androstenedione to oestrogen was calculated 
according to the formula:
3
H released as water (dpm) x 100
3
H added as androstenedione
Product Identification Assay
An assay system was set up as for the tritium release assay but 
using 1,2,6,7 H androstenedione (100 nm, 50 uCi, 250 x 10 dpm) as 
substrate in a total volume of 2ml (cofactors and substrate in 1ml 
+ 1ml of the soluble tissue fraction). The reaction was 
terminated after three hours by addition of methanol (2ml). 
Radioinert oestrone and oestradiol (500ug) were added to monitor 
manipulative losses.
The scheme used for the purification of oestrone / oestradiol and 
determination of their specific activity is outlined in Figure 2:2.
Steroids were extracted twice with ethyl acetate (5ml) and the
ethyl acetate layers were taken off, bulked and evaporated to 
dryness. The residue was dissolved in 4ml ether:petroleum ether 
(40-60°C) [1:1 v/v] and partitioned with IN. sodium hydroxide (1ml) 
three times. The ether:pet ether fraction was washed once with 
water (1ml) and the water combined with the sodium hydroxide 
extract. The sodium hydroxide extract was neutralised with sodium 
bicarbonate (0.56g) and re-extracted twice with ethyl acetate 
(2ml). The ethyl acetate fraction was evaporated to dryness, 
dissolved in ethanol (0.2ml) and spotted onto a silica gel TLC
plate and run in chloroform:acetone (98:2 v/v) for three hours with
oestrone and oestradiol standards. Oestrone and oestradiol 
fractions were visualised under u.v. light (375nm) and the
appropriate areas of the plates scraped off and eluted with ethanol 
after deactivation of the silica gel with a drop of distilled 
water. From this point the oestrone and oestradiol fractions were
Purification and specific activity determination of oestrone / oestradiol
Sample
t
sodium hydroxide extraction 
t
TLC in chloroform:acetone (98:2 v/v) 
t
oestrone / oestradiol fractions eluted separately
f
acetylation
t
TLC in cyclohexane:ethyl acetate (7:3 v/v)
t
hydrolysis
TLC in benzene-.ethyl acetate (4:1 v/v)
t
specific activity determination (oestrone / oestradiol)
t
acetylation
t
TLC in cyclohexane:ethyl acetate (7:3 v/v)
t
specific activity determination (oestrone acetate / oestradiol diacetate)
t
hydrolysis
t
TLC in chloroform:acetone (185:15 v/v)
t
specific activity determination (oestrone / oestradiol)
t
methylation
t
TLC in cyclohexane:ethyl acetate (55:45 v/v)
t
specific activity (oestrone methyl ether / oestradiol methyl ether)
Figure 2:2.
PRODUCT IDENTIFICATION ASSAY
purified and characterised separately to determine their specific 
activities.
The ethanol was evaporated to dryness and the oestrogens acetylated 
by adding acetic anhydride (6 drops) and pyridine (3 drops) and 
incubating at 60°c for 1 hour. Methanol (1ml) was added,
evaporated to dryness and the residue spotted onto a silica gel 
plate and run in cyclohexane:ethyl acetate (7:3 v/v) for 1 hour 
with appropriate standards. Oestrone acetate / oestradiol 
diacetate were visualised under u.v. light (280nm), scraped off, 
eluted with ethanol and dried down.
The acetates were then hydrolysed by dissolving in methanol (1ml), 
adding potassium carbonate (0.25ml, 2%) and incubating overnight at 
37°c. Distilled water (3ml) was then added and the steroid 
extracted twice with ethyl acetate (5ml) and evaporated to dryness. 
The residue was spotted onto a silica gel plate and run in 
benzene:ethyl acetate (4:1 v/v) for i hour with appropriate 
standards (oestrone + oestrone acetate or oestradiol + oestradiol 
diacetate). The free steroids were visualised and eluted as 
before.
The specific radioactivity of the fractions were determined at this 
stage by measuring both the radioactivity and the total oestrone / 
oestradiol associated with the fractions. The steroids were
3
dissolved in ethanol (5ml). H was determined by liquid 
scintillation counting of an aliquot (1/10) in Scintol 7 (10 ml). 
Total oestrone / oestradiol was measured by comparing u.v. 
absorption (280 nm) on a Unicam SP800 spectrophotometer with the
41
optical densities of authentic oestrone / oestradiol standards.
The free steroids were then acetylated and chromatographed as
before. Oestrone acetate / oestradiol diacetate was eluted and its
3
specific activity determined. H was determined by liquid
scintillation counting of an aliquot (1/5) in Scintol 7 (10ml). 
The acetates were measured by Gas Liquid Chromatography of an 
aliquot (1/10) on a five foot column of 3% 0V1 on Gas Chrom Q (100 
- 120 mesh - Applied Science Laboratories Inc.) at 223°C.
Testosterone acetate (lOug) was used as an internal standard.
The acetates were then hydrolysed and chromatographed as before. 
The free steroids were eluted and their specific radioactivity 
determined as previously using an aliquot (1/4) for liquid 
scintillation counting and measuring total oestrone / oestradiol by 
u.v. absorption.
The free steroids were then dried and methylated by the addition of 
distilled water (10ml), boric acid (0.18g), sodium hydroxide 
(0 .8ml, 20%) and dimethyl sulphate (0 .2ml), and incubation for
3Qmins at 37°C. A further 0.4ml of 20% sodium hydroxide and 0.2ml 
of dimethyl sulphate were added and the mixture incubated for a 
further 30 minutes. Sodium hydroxide (2ml, 20%) and hydrogen
peroxide (0.5ml, 30%) were then added and the steroids extracted 
into petroleum ether (25ml).
The oestrone / oestradiol methyl ethers were chromatographed in 
cyclohexane .-ethyl acetate (55:45 v/v), visualised under u.v. light,
3
eluted and their specific activities determined. H was
42
determined by liquid scintillation counting of an aliquot (1/3) in 
Scintol 7 (10 m l ). The methyl ethers were measured by Gas 
Chromatography of an aliquot (1/5) using testosterone (lOug) as an 
internal standard (conditions as before).
If the oestrone / oestradiol fractions are pure, the specific 
activities of the free steroid, the acetate and the methyl ether 
will be constant. Purification by chromatography and chemical 
derivative formation continued until the three specific activities 
differed by less than 10%.
The % conversion of androstenedione (A) to oestrone (E^) was 
calculated as follows:
3
H in E^ recovered x cold E^ added x 100 
-
H in A added x cold E^ recovered
which may be simplified to
Specific radioactivity of E^ recovered x cold E^ added x 100
_
H in A added
A similar calculation is used to determine the conversion to 
oestradiol, and the two figures added to derive the total oestrogen 
formation.
Results:
These are shown in Table 2:1.
TABLE 2;1.
PRODUCT IDENTIFICATION ASSAY
STEROID COLD STEROID 
(nm)
dpm Spec. Act.
FREE OESTRADIOL 970 1650 1.7*
FREE OESTRONE 936 4135 4.42
OESTRONE ACETATE 798 3339 4.18
FREE OESTRONE 410 1610 3.93
OESTRONE METHYL ETHER 267 1150 4.31
AVERAGE SPECIFIC ACTIVITY (OESTRONE) =4.21
PERCENTAGE CONVERSION (OESTRONE) = 0.021%
TRITIUM RELEASE ASSAY
TIME TOTAL dpm
(hrs) BLANK TISSUE %C0NVERSI0N
0 54735
I
! 48658
I
3 82035 ! 130373
I
I
1.00
* The specific activity of oestradiol at the first estimation was
1.7 equivalent to a % conversion of 0.008. With such a low conversion, 
no further purification of oestradiol was performed. Even if this
activity were maintained throughout the subsequent steps total
conversion (ie oestrone + oestradiol) is unlikely to exceed 0.03%.)
Comment:
There is considerable discrepancy between the two assays, with 
apparently greater activity in the "tritium release assay". There 
are several possible explanations for this: further metabolism of 
the formed oestrogens could occur leaving only small amounts of 
labeled oestrogen to be detected in the "product identification 
assay" (subsequent experiments however, suggest that further 
metabolism of oestrogens in 3 hour incubations is negligible). 
Alternatively, in the tritium release assay there could be 
non-specific release of tritium into aqueous products or 
contamination of the aqueous extracts by radiolabeled steroids.
44
Modification of the Tritium Release Assay,
A series of modifications were introduced to the tritium release 
assay to eliminate contamination of the aqueous extracts by 
steroids, reduce non-specific release of tritium and maximise the 
detectable aromatase activity.
The modifications which significantly improved the assay are 
outlined in the following sections.
Modification 1.
Reduction of steroid contamination of the aqueous fractions by 
extracting the non-polar steroids into chloroform.
Method:
Incubations were performed with ovarian microsomes as substrate. 
Extraction procedures were compared as follows:
A. Standard extraction: 2 x 200ul aliquots of incubate each 
extracted with 800ul of 1.625% activated charcoal (20 mins), 
samples then centrifuged and supernatants decanted for counting.
B. Modified extraction: 500ul aliquot of incubate dispensed into 
3ml of chloroform and thoroughly shaken then centrifuged. 2 x 
200ul aliquots were then removed from the aqueous phase and 
extracted with charcoal as in A above.
Duplicate counts were therefore obtained for each time point. The 
two were then averaged to calculate the total dpm.
Results: The results are shown in Table 2:2.
Conclusion: Chloroform extraction markedly reduces the levels of
radioactivity detected in the aqueous extracts, presumably by 
reducing steroid contamination.
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Modification 2.
Increasing the concentration of charcoal in the extractions.
Method:
Two parallel incubations were performed as in ' IB above 
(incorporating the chloroform extraction). In incubation A
extraction was performed with 1.625% charcoal, in incubation B with 
5% charcoal. Ovarian microsomes were again used as substrate.
Results:
The results are shown in Table 2:3. These reveal a significant 
reduction in the levels of radioactivity being detected in the 
aqueous extracts.
To investigate if contamination of the aqueous extracts by 
radiolabeled steroids was still occuring, a further incubation was 
performed with one aliquot being dispensed into scintillant and 
counted as before. The second aliquot was evaporated to dryness 
under a continuous stream of nitrogen to eliminate any tritiated 
aqueous products. 1ml of distilled water was then added together 
with scintillant and the mixture counted in the usual manner.
Evaporation of the duplicate aliquots revealed that there was no 
longer any significant contamination of the aqueous extracts by 
labeled steroids.
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Modification 3.
The use of a concentrated "particulate fraction" of adipose tissue. 
Prolonging the incubation time.
Reducing the amount of radiolabeled substrate.
Further improvement in the assay required either a reduction in the
non-specific release of tritium or a relative increase in the
specific tritium release. Non-specific release of tritium should
be decreased by reducing the quantity of radiolabeled substrate in
each incubation. Specific release of tritium due to oestrogen
formation could be enhanced by allowing the reaction to run for a
longer time and by including more tissue in each incubation.
(Nimrod & Ryan have reported that this can be achieved by
precipitating particulate fractions from larger quantities of 
115
adipose tissue .)
Preparation of Particulate Fraction:
5grams of adipose tissue were homogenised in buffer to produce 5mls 
of soluble extract as before. 1ml was retained for the standard 
incubation while the remainder was centrifuged at lOO,OOOg for 1 
hour and the resulting pellet (particulate fraction) resuspended in 
0 .6ml of buffer. 0.5ml being used in the incubation.
Substrate:
3
luCi of H androstenedione was substituted for the 2.5uCi 
previously used. Appropriate adjustments were made to the amount of 
"cold" substrate being added in order to maintain the overall 
concentration of androstenedione at lOOnm.
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Reaction time:
The reaction was allowed to proceed overnight (17hrs).
Results:
The results are shown in Table 2:4.
Comment:
The levels of counts now being observed in the assay are markedly 
reduced in comparison to the original experiments. However, the 
fact that significant amounts of tritium are being released at the 
start of the reaction suggests that non-specific release of tritium 
can still occur readily.
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Modification 4.
3 3
Substitution of 1-beta H androstenedione for 1-beta,2-beta H
androstenedione as substrate.
A number of reports have suggested that the 2-beta tritium is 
unstable and is liable to be released non-enzymically leading to 
high levels of background c o u n t s ^ ' T h e  effect of using 
1-beta tritiated substrate rather than the 1-beta,2-beta tritiated 
substrate was therefore studied.
Substrate:
3 3
1-beta H androstenedione was prepared from 1-beta,2-beta H
12
androstenedione using the method of Berkovitz et. al. . This 
involves overnight incubation with methanol/0.1 N NaOH (9:1, 
vol/vol). The steroid was then.extracted with methylene chloride 
and purified by thin layer chromatography in chloroform:acetone 
(185:15).
Incubations:
2 parallel sets of incubations were performed, each with an albumin 
"blank", and a particulate preparation of adipose tissue. luCi
3
of 1-beta,2-beta H androstenedione was used as substrate in the
3
first set and luCi of 1-beta H androstenedione in the second. 
Appropriate adjustments were again made to ensure that the overall 
concentration of androstenedione remained at lOOnm in all 
incubations.
Aliquots (350ul) were withdrawn at two time points (Ohrs & 3hrs) 
and the remainder (400ul) was used for the final (17hr) estimation. 
Single aliquots of 200ul were counted for each time point.
49
Results:
The results are shown in Table 2:5.
Comment:
3
Use of the 1-beta H androstenedione significantly reduced the 
counts in both the "blank" and the tissue incubations at all time 
points. This is consistent with a reduction in the non-specific 
release of tritium.
50
> in CM0 G o CMc o •o o o o 0•h ae G
dj O
0 cq •ric P T)
0 < 0 •P h-J ~ c >1W D S cd in CM 0 0o a vo CD O -p 0k t-i rH CM o 010
tD H w rH CM o 0c Pi u0 < TJ 0PU G 0w 0 0
H 0Sq r—H
<Q s S vo K 0rH f< a CM in H Ufl TJ in CD opq w CT> rH CD aCQCM•rH•.p> CQ •rHc CD CM rH
0 o rH -pc o • •
o ae o o rG 0•ri P .C■d •rHp0 M £G P c0 r=C 0 •HP i-l q c
0 D S Ch rH 0 0o o p VO CD in •1-1P*-« t3 CM o TJ 0
tJ H w rH h* o 0 uc Pi CM G p0 0Ph -P,Q
W 0 3
H O 0uin *d 0CM g g CM Ch G 0* flj P CO CD 0CQ Pti rH CD CM
*H CQ w rH CM rH K
n
H oi CQpEj 5h rHV—t ,C o CD £"-
H rH PO
, c
in o• 0CM •rH
w 0
PI P
PQ s< 0
E» o
Validation experiment A.
Measurement of the loss of tritium which occurs during the tritium
release assay.
Introduction
An important factor which will influence the accuracy of the 
tritium release assay is any loss of tritiated water which occurs 
during the procedure. Such losses have to be quantified before 
valid comparison with the product identification assay is possible. 
Aim:
To quantify the loss of tritiated water that occurs during the 
tritium release assay.
Materials & methods:
Tritium labeled water/aqueous products was obtained by incubating 
luCi of 1-beta, 2-beta androstenedione with placental microsomes 
and an NADPH-generating system, followed by extraction with
chloroform and activated charcoal. 150ul aliquots were dispensed
into distilled water (850ul) and either counted (n=3) or subjected 
to standard incubation conditions (shaken for 3 hours at 37.C) 
followed by chloroform and charcoal extraction (n=3). Total counts 
in the "incubated" samples were then compared with counts in the 
non-incubated samples to determine the loss of tritium occuring 
during the assay.
Results:
Total cpm
Non-incubated samples Incubated, samples
1. 83027 1. 65473
2. 84640 2. 70873
3. 82325 3. 66148
Mean 83330 67498
Average recovery of tritium = 67498 X 100 %
83330
81%
Conclusion: 19% of tritium is lost during the assay procedure.
Results should therefore be adjusted to correct for this.
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Validation experiment B.
Variation of substrate concentration.
Introduction.
2 12 29 53
Investigation of the aromatase enzyme(s) by others ' ' '
reveals classical Michaelis-Menton kinetics in that the enzyme can 
be saturated by increasing concentrations of substrate. The 
concentration of androstenedione in breast adipose tissue is 
reported to vary between 10 and 20Qnm'^'^. The concentration of 
substrate (lOOnm) used in the standard assay was therefore chosen 
to reflect physiological substrate availability.
Aim:
To investigate the enzyme kinetics of the tritium release assay to 
determine if physiological substrate concentrations are appropriate 
for this assay system.
Method:
A particulate.fraction was prepared from 4 grams of adipose tissue. 
Four parallel incubations were then performed with the standard 
concentrations of cofactors, but with the following concentrations 
of androstenedione: 33nM, 75nM, 150nM, & 200nM (achieved by
varying the amount of radioinert androstenedione added to each
3
incubation. Each incubation still contained luCi of 1-beta H 
androstenedione)
Results:
The assay results are presented in Table 2:6 and Figure 2:3 . The
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Figu r e  2:3
The effect of increasing s u b s t r a t e  c o n c e n t r a t i o n  
on aromatase a c t i v i t y  in adipose tissue.
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L i n e w e a v e r - B u r k e  plot of aromatase ac t i v i t y  
in adipose tissue.
Lineweaver-Burke plot of the results is shown in Figure 2:h . 
(correlation coefficient = 0.996, Km = 132nm, Vmax = 89 fmol/mg 
prot/hr.)
Comment:
These results confirm that in this assay, the reaction follows 
classical Michaelis-Menton kinetics. Physiological concentrations 
of androstenedione (l0-200nM) do not produce enzyme saturation. 
The results from the present assay should therefore reflect 
physiological activity rather than maximal enzyme activity.
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Modified tritium release assay.
With incorporation of the foregoing modifications into the "tritium 
release" assay, the assay procedure has now been finalised and is 
outlined below and summarised in Figure 2:5.
Aromatase Assay (Tritium release)
Cofactors [nicotinamide (lQmM), MgCl2 (5mM), glucose 6-phosphate 
(lOmM), glucose 6-phosphate dehydrogenase (2u/ml) and 2 mM each of 
NAD, NADP and ATP] and substrate [ 100 nM 1-beta
androstenedione (1 uCi)] were pre-incubated at 37°C in a total 
volume of 600 ul phosphate buffer (O.lM, pH 7.4). Enzyme 
reactions were started by addition of the particulate 
fraction (500 ul) to substrate and co-factors. Blank 
incubations were also set up using 500 ul of bovine serum albumin 
(2.0 mg/ml) in place of the particulate fraction. Incubations 
were then performed overnight at 37°C with continuous shaking. An 
aliquots (550 ul) of the reaction mixture was removed into 3 ml 
of ice-cold chloroform after 3 hours, the remainder being left to 
incubate overnight and the reaction terminated by addition of a 
further 3mls of ice cold chloroform. The aliquots + chloroform 
were thoroughly shaken, and centrifuged at 2000g for 3 minutes to 
terminate the reaction. An aliquot (400 ul) of the resulting 
aqueous fraction was added to 5% charcoal solution (800 
ul), mixed, and allowed to stand for 10 minutes with 
occasional further mixing. The charcoal was then 
precipitated by centrifugation at 2,000 g for 15 minutes and 
the supernatant decanted into a glass counting vial containing NE 
260 Scintillation fluid (10 ml). Radioactivity was measured on
54
2 grams of adipose tissue homogenised in phosphate buffer (2ml).
t
centrifuge (800g 5 minutes)
V
supernatant centrifuged (100,000g, 1 hour)
V
pellet (particulate fraction) resuspended in buffer (600 ul).
3 *
Cofactors + 1-beta h androstenedione (600ul) pre-incubated 37°C
Particulate fraction or Blank (500ul) added to substrate + co-factors.
V
Incubate overnight (37°C) with continuous shaking.
t
Aliquot (550 ul) into 3 ml chloroform at 3 and 18 hours.
t
Aliquots + chloroform shaken + centrifuged (2000g 3mins).
t
Aliquot (400 ul) of aqueous fraction + 5% charcoal solution (800ul), mixed
t
Centrifuge (2,000g, 15 mins).
3 *
Count H in supernatant (NE 260 Scintillation fluid 10 ml).
3 3 * 3
H m  incubation - H in blank = H released.
t
Correct for procedural losses, counting efficiency.
Figure 2:5.
TRITIUM RELEASE ASSAY
a Packard Tri-Carb Liquid Scintillation spectrometer. Counts 
obtained in the blank incubations were subtracted from all other 
counts before correction for procedural losses and counting 
efficiency.
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Validation experiment C.
Comparison of the modified tritium release assay with the product
identification assay.
Materials & methods:
A series of three parallel incubations were performed on three 
separate occasions using adipose tissue samples from successive 
breast cancer patients. On the first occasion product 
identification assays were performed for 3 hours and overnight (18 
hours). An aliquot from the tritium release assay being taken at 3 
hours and the remainder allowed to incubate overnight. For the 
next two comparisons all incubations were performed for 3 hours.
Results:
The results are shown in Table 2:7.
Discussion:
In the 3 hour incubations the tritium release assay has detected 
68%, 70% and 67% of the activity measured by the product
identification assay. These figures are consistent with the
156 2
findings of Thomson & Si iter i and Ackerman et al who have noted
that only 70% of the tritium in the 1C position is released when
oestrogen is formed. There is no correlation however, between
the assays for the overnight incubations. This presumably
reflects further metabolism of oestrogens in the overnight
incubations (since less radioactively labeled oestrogen is present
after 20 hours than at 3 hours). The validity of overnight
incubations is therefore difficult to verify so it was decided to
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proceed only with 3 hour incubations.
If this correlation is consistently reproducible, then it appears 
that the tritium release assay can accurately measure oestrogen 
formation in adipose tissue.
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Validation experiment D.
Aim.
a) Further comparison of the tritium release and product
identification assays.
b) Verification that the assays are measuring activity of the 
aromatase enzyme(s) by incorporating aromatase inhibitors
(aminoglutethimide and 4-OH androstenedione) in both assay systems.
Materials & methods:
As before, apart from: 20g of adipose tissue (obtained from patient 
10) was used to produce 5ml of particulate fractions. 3 pairs of 
parallel incubations were performed by the two methods - a) No 
inhibitor, b) + O.lmM aminoglutethimide, c) + O.luM 4-OH 
androstenedione (such concentrations are known to inhibit aromatase
activity in assay systems utilising extracts of placenta, ovary and
u . . 21,106,110,120,167xbreast tumours ' ' ' ' ).
Results:
See Table 2:8.
Comment:
Again there is a consistent relationship between the results of 
the two different assays with the tritium release assay recording 
73%, 66%, and 75% of the activity detected in the product
identification assays. In addition, there has been about 50% 
inhibition of activity by aminoglutethimide and 40% inhibition by 
4-OH Androstenedione. While such inhibition is not as marked as 
that obtained in other tissues (placenta, ovary,
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tumour ) it is important to have established this
effect since these agents appear to be able to reduce peripheral
aromatase in vivo^.
In six comparisons which have been made between the assays for 3 
hour incubations the tritium release assay has detected activity 
which is between 66 and 75% of that measured by the product 
identification assay. The average discrepancy between the assays 
is 70% and is thus in keeping with the observations of others '
3
that only 70% of the tritium is released from 1-beta H 
androstenedione when oestrogen is formed.
If the tritium release results are adjusted to correct for this 
discrepancy (by dividing the results by 0.70) the comparison of the 
two assays is as shown in Table 2:9 and Figure 2:6, revealing an 
excellent correlation (correlation coefficient = 0.988 p< 0.001).
The tritium release assay in its present form therefore appears to 
be a suitable assay for the measurement of aromatase activity in 
adipose tissue.
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C o m p arison of the product e x t r a c t i o n  and t r i t i u m  r e l e a s e  
assays for aromatase a c t i v i t y  in adipose tissue.
Validation experiment E.
Aim:
To investigate the relationship between the quantity of adipose 
tissue assayed, the protein concentration of particulate fractions 
and aromatase activity.
Method:
Six grams of breast adipose tissue was obtained from one patient 
and homogenised to produce 6 mis of soluble extract. This was 
divided into aliquots of 1, 2, & 3 mis from which particulate
fractions were prepared, each being resuspended in 600ul of buffer. 
500ul of this suspension was incubated in the standard tritium 
release assay and the remainder retained for protein estimation. 
Protein estimation:
17
The protem-dye binding method of Bradford was utilised. Aliquots 
(50ul) of the resuspended particulate fractions were added to 0.9% 
NaCl (250ul). Duplicate aliquots (lOOul) were then thoroughly mixed 
with 5ml of an acidified solution of Coomassie Brilliant Blue G-250 
[lOOmg dissolved in 95% ethanol (50ml), 85% phosphoric acid (lOGml) 
diluted to a final volume of 1 liter]. Absorption was measured at 
595nm on a Unicam SP600 spectrophotometer against a reagent blank.
Results: The results are outlined in Table 2:10.
Comment: It is clear from these results that aromatase activity
in a particulate fraction of adipose tissue is directly related to 
the protein concentration of the tissue extracts which is in turn 
related to the quantity of tissue included in the assay.
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Validation experiment F.
The effect of tissue storage.
Aim:
To determine the effect on assay results of storing adipose tissue 
at -20°C and -196°C.
Introduction
The study of a large series of tissue samples is facilitated if 
samples can be stored after collection without significant loss of 
enzyme activity. The purpose of this experiment was to investigate 
the effect of tissue storage on assay results.
Materials & methods:
Four grams of tissue was obtained from each of nine patients. 
After separation of adipose tissue from parenchyma and fibrous 
tissue two grams was assayed immediately and the remaining two 
grams stored in liquid nitrogen (-196°C n=7) or in the deep freeze 
(-20°C n=2). Storage time varied from 2 days to 2 months (Table
2:11) before tissue was removed thawed and assayed. Ten grams of 
tissue was obtained from a further case. Two grams was assayed 
immediately and the remainder stored in 2 gram aliquots (-196°C) 
for assay after various storage times. All assays were performed by 
the tritium release method outlined previously. At the time of 
assay aliquots were taken from all samples for protein estimation.
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Results.
The results of the nine paired assays are shown in Table 2:12, and
the multiple assay results from patient No 42 in Table 2:13.
Conclusion.
The results indicate that there is negligible loss of enzyme 
activity with storage of tissue at these temperatures for up to 
three months. The results again highlight the importance of the 
protein concentrations of the tissue extracts in relation to enzyme 
activity. Although in the majority of cases only small variations 
in protein concentration occured, occasional larger differences are 
seen - with quite a marked effect on assay results. Such
differences could be due to the heterogeneity of the tissue being
sampled or to variable tissue processing. Whatever the cause of 
the variation, assay results were more reproducible if expressed in 
terms of the amount of protein present. Since levels of protein 
are likely to be a reflection of the cellularity of the tissue, 
this will to some extent correct for variations in cellularity 
between tissue samples.
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Chapter 3.
Aromatase activity in breast adipose tissue from women with benign 
and malignant breast conditions.
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Aim:
To compare aromatase activity in breast adipose tissue samples from 
women with breast cancer and non-malignant breast conditions. 
Materials & methods:
Patients:
Adipose tissue was obtained from breast cancer patients at the time 
of mastectomy or wide local excision and from patients having 
excision biopsies performed for benign conditions. Prior to 
surgery, some of the breast cancer patients had been treated by 
radiotherapy, hormonal therapy and/or chemotherapy. Full details 
of the patients studied are given in Tables A:1 and A:2 in appendix 
A. A brief summary of patient details is given in Table 3:1. 
Patients were considered to be post-menopausal if more than 3 years 
had elapsed since their last menstrual period. Histological 
details and results of oestrogen receptor analyses on the 
associated mastectomies/breast biopsies are given in Tables A:3 and 
A:4 in appendix A.
Tissues:
At operation adipose tissue close to the site of the breast 
lesions was removed and transferred to the laboratory on ice. 
All procedures, were then performed at 4°c unless otherwise 
stated. Samples were rinsed in 0.1M phosphate buffer 
before carefully dissecting adipose tissue free from breast 
parenchyma and fibrous tissue. Samples were then stored at 
-196°C until assayed.
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Assays:
Tritium release assays were performed on particulate fractions from 
the tissue samples according to the method in Chapter 2. Results 
are expressed as fmol oestrogen/mg protein/hr (units) on the 
basis of the conversions at 3 hours.
Statistics:
Statistical analyses were by the Wilcoxon rank test.
Results:
Oestrogen biosynthesis was detected in all samples of breast 
adipose tissue examined with activities varying from 3.1 to 114 
fmol oestrogen produced / mg protein / hour (units). Individual 
assay results are shown in Tables B:1 and B:2 in Appendix B. The 
results are compared in Figure 3:1 which shows that the median 
activity in tissue from breast cancer patients (27.0 units) was 
more than two-fold higher than that in samples from women with 
benign conditions (12.3 units). The difference between the 
groups was significant (p < 0.0001).
As measurements were performed in consecutive patients from whom it 
was possible to obtain sufficient tissue for analysis, the groups 
have not been matched in any respect and therefore it is important 
to look for correlations with other factors which might influence 
oestrogen biosynthesis. The relationship with age of the subjects 
is plotted separately in Figure 3:2 for patients with either benign 
or malignant lesions. In neither group of patients was there an 
obvious relationship between levels of activity and age, although a 
tendency was apparent for the highest levels of aromatase to be
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found in breast fat from cancer patients between 40 and 55 years of 
age. The effect of menopausal status on aromatase activity in 
breast fat from cancer patients is shown in Figure 3:3. The 
median value (32 units) in pre- and peri-menopausal patients was 
higher than that in post-menopausal patients (23 Units), but the 
difference was not statistically significant. Meaningful analysis 
of the benign group was not possible because of the small number of 
post-menopausal women with non-malignant breast conditions. Since 
there were marked differences between the cancer and benign groups 
in terms of both age and menopausal status, it was of interest to 
compare results using pre- and peri-menopausal patients only, thus 
minimising the age discrepancy between the groups. As is shown in 
Figure 3:4, aromatase activity remained significantly higher in the 
cancer group (p < 0.0001).
To determine whether the previous treatment of some of the breast 
cancer patients could account for the differences seen, levels of 
aromatase activity in the previously treated group were compared 
with activities in the group of untreated cancer patients (Figure 
3:5). There was no significant diference in levels of activity 
between the two groups. Additionally, within the group of 
previously treated cancer patients there was no difference in the 
levels of aromatase activity between those who responded to 
systemic therapy compared with those who failed to respond (Figure 
3:6). Comparison of aromatase activities between the untreated 
cancer patients and the benign disease group confirms that 
significantly higher activity is still present in this group of 
cancer patients (Figure 3:7).
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The results were also analysed with regard to height, weight,
2
obesity (Quetlet index, wt/ht ), parity, age at menarche, age at 
first full term pregnancy, and family history of breast cancer 
(Figures 3:8-3:14) but no trends were detected. Furthermore, in 
the cancer group there was no relationship between aromatase 
activity and tumour type, size or oestrogen receptor protein 
content. (Figures 3:15-3:17).
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Discussion.
This study demonstrates the potential for oestrogen biosynthesis in 
all specimens of breast adipose tissue examined. Levels were of a 
similar magnitude to those reported by others in adipose tissue 
from various body sites'^'
An important observation was that despite the large variation in 
levels of aromatase activity between different specimens of adipose 
tissue, activity was significantly higher in tissue obtained from 
women with breast cancer compared with that in adipose tissue from 
women with benign lesions. Others have failed to detect such a 
d i f f e r e n c e " ^ b u t  have studied very small numbers of patients. 
The larger study of Beranek and co-workers also reported no 
significant difference between cancer and control patients but 
employed less sensitive assay conditions utilising soluble rather 
than particulate fractions’^ .  Nevertheless aromatase activity 
was detected in 82% of cancer cases compared with only 50% of those 
with benign conditions suggesting a trend towards enhanced 
aromatase activity in adipose tissue from breast cancer patients.
There are two possible explanations for the presence of higher 
aromatase in breast adipose tissue from breast cancer patients, 
namely, either (1) malignant tumours are capable of stimulating 
aromatase activity in surrounding tissues or (2), regionally 
enhanced aromatase activity in adipose tissue produces a local 
environment which promotes malignant growth at that site.
With regard to the former possibility recent data suggest that 
growth factors enhance aromatase activity in peripheral tissues^^.
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These include factors which may be produced in a paracrine manner 
93
by tumours and preliminary results indicate that the addition of
extracts from breast cancers added to cultures of adipose tissue
130
may stimulate oestrogen biosynthesis
Since oestrogens are heavily implicated in the promotion of breast
91 154
cancer ' local areas of enhanced oestrogen production might be 
expected to encourage development of tumour foci at these 
favourable sites. If this is the case one would expect a
particular association between high aromatase activity in adipose 
tissue and oestrogen receptor positive tumours which are more 
likely to be oestrogen responsive. However such an association 
was not found in the present study. The possibility cannot be 
excluded, however that the tumours which were oestrogen receptor 
negative at the time of surgery were oestrogen receptor positive at 
an earlier stage in their evolution and have now become oestrogen 
independant.
As breast cancers in general have higher aromatase activity than 
1 123
adipose tissue ' the higher activity in adipose tissue from
breast cancer patients could also be due to the presence of 
micrometastatic deposits of malignant cells within the adipose 
tissue. Whilst this possibility cannot be completely excluded, 
portions of fat adjacent to that used for the aromatase assay were 
not shown to be involved microscopically with cancer.
Although levels of aromatase activity were higher in fat from 
breast cancer patients, a large range of values was found in 
patients with and without malignant breast disease. It is clear
69
therefore that other factors must influence the aromatase system.
Statistically significant relationships were not observed between
aromatase activity and age or menopausal status of the patients
from whom the samples were obtained, although the highest levels of
activity were observed in women aged between 40 and 55. This trend
55
is similar to that noted m  a study of abdominal adipose tissue .
However in view of the relative excess of pre-menopausal women in
our benign group as compared with cancer patients and the reports
28 57
of others that peripheral aromatase increases with age ' , the
data was reanalysed excluding post-menopausal women. The 
difference in aromatase activity between the cancer patients and 
the non-malignant group remained highly significant, so it is 
therefore extremely unlikely to be an age related phenomenon.
There was no significant relationship between aromatase activity 
and various factors which are associated with excess risk of breast 
cancer such as height, weight, obesity , parity, age at menarche, 
age at first full term pregnancy, or family history of breast 
cancer. The differences between cancer and control patients are 
therefore unlikely to be due to any excess of these risk factors in 
the cancer group. Factors which influence the inherent level of 
aromatase in breast adipose tissue still therefore require to be 
identified.
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Chapter 4.
Comparison of aromatase activity in breast adipose tissue 
adipose tissue from other body sites.
with
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Introduction
If steroid metabolism in breast adipose tissue is of relevance in 
the evolution of breast cancer then levels of aromatase activity in 
the breast should at least be comparable with the activity found in 
other body sites. It has been suggested that activity in breast 
adipose tissue is lower than activity elsewhere in the body"^. In 
that study, however, comparisons were made between samples from 
different individuals. The aim of this investigation was to 
compare aromatase activity in breast adipose tissue with that in 
samples from other sites in the same individual.
Methods.
Adipose tissue was obtained simultaneously from the breast and from 
another body site in six patients undergoing other surgical 
procedures in addition to breast surgery. The sites from which 
tissues were obtained are shown in Table 4:1.
Results:
The results are shown in Table 4:1. Levels of aromatase activity 
are comparable when expressed in terms of activity per gram of 
adipose tissue. Extracts of adipose tissue from other sites 
contained higher concentrations of protein suggesting that these 
samples were more cellular. The breast samples were more active if 
results are expressed in terms of activity per milligram of protein 
in the tissue extracts. (Figure 4:1, p < 0.05)
Conclusion:
Although this is a small series of patients the results indicate 
that breast adipose tissue is as active as tissue elsewhere in the 
body in terms of aromatase activity.
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Chapter 5.
Aromatase activity in adipose tissue from breast quadrants of
patients with breast cancer.
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Introduction
The results in Chapter 3 suggest that breast cancer is associated
with enhanced aromatase activity in adjacent adipose tissue.
Breast cancers occur predominantly in the upper outer quadrant of 
70
the breast . It remains to be determined whether aromatase 
activity in adipose tissue varies throughout individual breast 
quadrants. The aims of this study were therefore to: a) 
investigate if aromatase activity varies between different 
quadrants of the same breast by measuring activity in adipose 
tissue from the mastectomy specimens of patients with breast 
cancer, and b) determine if there is any consistent pattern of 
distribution of aromatase activity in relation to the quadrants of 
the breast or the location of the tumours.
Materials & methods
Tissues:
Adipose tissue was obtained from the four quadrants of 
twelve consecutive mastectomies performed for histologically 
confirmed breast cancer and carefully separated from breast 
parenchyma or fibrous tissue. (Patient numbers are given in 
Table 5:1, further details of these patients are included in 
Appendix Tables Al and A3.)
Aromatase assay
Particulate fractions from the adipose tissue samples were 
incubated in tritium release assays as previously described.
74
Statistical methods
Aromatase levels in the four breast quadrants were compared using 
the Friedman test, and average levels in the tumour-bearing 
quadrants were compared to average levels in quadrants not bearing 
tumours by the Wilcoxon signed-ranks test. Multiple regression 
analysis on the logarithms of the 48 aromatase activities was used 
to test the combined association of tumour and anatomical location 
on the aromatase level. The analysis treated patient, location 
and presence or absence of tumour as fixed effects with 12, 4, and
2 levels respectively, and these tests were performed for the
significance of location, controlling for patient and tumour, and 
of tumour controlling for patient and location.
Results:
Aromatase activity was detected in all samples studied (range 3.6 - 
35 units) Considerable variation was observed between 
individuals (average values 6.3 - 26.9 units) and between
different quadrants in the same breast, the ratio of activity in
the most to the least active quadrants ranging from 1.4 to 4.9
(Table 5:1 - full details of the results are given in Appendix 
Table B5). There was a significant association between the 
anatomical location of the quadrant and levels of aromatase 
activity (p < 0.05). The highest activity was present in the upper 
outer quadrant in seven cases, the lower outer quadrant in three 
and the upper inner quadrant in two. The lower inner quadrant 
was never the site of highest activity but represented the 
least activity in five cases. The upper inner quadrant held 
the least activity in four cases and the lower outer quadrant 
the remaining three. The upper outer quadrant never exhibited
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TABLE 5:1. Adipose Tissue Aromatase Activity in Breast Quadrants
(Figures in brackets - ratio of activity to lowest activity in that breast)
Patient Aromatase Activity in Breast Quadrants
LIQ loq UIQ UOQ Mean
4. 10.5* 15.0* 6.2 9.5 10.3
(1.7) (2.4) (1) (1.5)
9. 7.7 7.1 34.9* 12.3 15.5
(1.1) (1) (4.9) (1.7)
11. 22.9 27.4 24.9 32.2* 26.9
(1) (1.2) (1.1) (1.4)
14. 26.0 23.9 23.6 32.0* 26.4
(1.1) (1) (1) (1.4)
15. 15.0 35.0* 10.5 17.8* 19.6
(1.4) (3.3) (1) (1.7)
18. 3.6 3.6 10.8* 7.2* 6.3
(1) (1) (3.0) (2.0)
23. 4.9 10.3 10.5 23.7* 12.4
(1) (2.1) (2.1) (4.8)
26. 5.6 7.1 12.2 14.0* 9.7
(1) (1.3) (2.2) (2.5)
33. 9.9 19.0*+ 13.9*+ 13.1*+ 14.0
(1) (1.9) (1.4) (1.3)
34. 10.9 5.2 8.2 15.9* 10.1
(2.1) (1) (1.6) (3.1)
39. 9.7 12.3 12.5 15.4* 12.5
(1) (1.3) (1.3) (1.6)
47. 11.7 14.0+ 6.2 17.3* 12.3
(1.9) (2.3) (1) (2.8)
* Quadrant containing clinically detected tumour 
+ Additional tumour foci discovered on histology
LIQ - Lower Inner Quadrant LOQ - Lower Outer Quadrant 
UIQ - Upper Inner Quadrant UOQ - Upper Outer Quadrant
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the lowest activity.
The relationship of activity to the sites of clinically 
and pathologically detected tumour is shown diagrammatically in 
Figure 5:1. In 8 cases the main tumour mass was located entirely 
in one quadrant: in all 8 this quadrant had the highest
activity. In patient 47. a second focus of tumour was detected 
in the lower outer quadrant which had the second highest activity. 
In three cases the tumour mass straddled two quadrants both of 
which had higher activity than the non-involved segments. The 
remaining case had invasive tumour in three quadrants but no 
tumour in the quadrant with lowest activity.
Levels of activity were therefore strongly correlated with the 
presence of tumour in a quadrant: in all twelve cases the average
level in the tumour-bearing quadrants was higher than in those not 
bearing tumours (p < 0.001). The mean ratio of aromatase activity 
in tumour bearing quadrants as compared to those not bearing 
tumours is estimated as 1.89, with 95% confidence limits of 1.56 
and 2.31 . A multiple regression analysis reveals that whilst 
there was no significant difference in activity between the 
various quadrants after correction for the presence or absence 
of tumour, the activity was significantly correlated with the 
presence of tumour in a quadrant irrespective of its anatomical 
location {t = 5.45, 32 d of f, p < 0.001). No relationship was 
apparent between the average individual activity and the patient's 
height, weight or obesity, nor was there any link with tumour type, 
size or stage.
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Discussion
All samples of mammary adipose tissue again possessed aromatase
activity but there was large variation in levels not only
between different patients but also within individual breasts.
Whilst the variation within the breast had some anatomical basis
the level of activity was much more significantly related to the
presence of tumour in a quadrant with activity in tumour-bearing
quadrants being between one and a half to two and a half times the
level in other quadrants. The trend for high activity to be
present in the upper outer quadrant probably reflects the more
frequent occurence of tumours in this location as seen in the
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present study and as reported elsewhere
The increase in aromatase activity in tumour bearing quadrants is 
unlikely to be due to increased cellularity of the tissues in these 
quadrants. Increased cellularity would be reflected in a higher 
protein concentration of tissue extracts. The protein 
concentrations of samples were relatively consistent within 
individual breasts and were not highest in tumour-bearing 
quadrants.
Several reasons could account for the enhanced aromatase activity
in quadrants containing tumours. Breast cancers in general show
1 123
higher aromatase activity than adipose tissue ' , and it is
possible that adipose tissue samples from tumour-bearing quadrants 
contain micrometastatic deposits of tumour. This cannot be totally 
excluded but there was no evidence of tumour deposits in samples of 
adipose tissue examined histologically. Furthermore the adipose
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tissue was taken from the periphery of breast quadrants in areas 
remote from the palpable tumour in order to minimise the risk of 
including tumour foci within the samples.
Assuming that elevated aromatase activity in tumour bearing 
quadrants is not due to contamination of samples by tumour cells, 
the results would still be in keeping with the suggestion that 
regionally enhanced aromatase activity in adipose tissue may be 
producing a local environment which promotes malignant growth. 
Alternatively malignant tumours may be capable of stimulating 
metabolic activity in their surrounding tissues. This effect could 
be specific for the aromatase system or may be part of an increase 
in several enzymes. Such an effect could result from the 
production of specific substances which stimulate these particular 
enzymes or could be due to an indirect effect of tumours on their 
surrounding tissues, e.g. by increasing cellularity or vascularity. 
It should be possible to determine if there is a non-specific 
increase in metabolism around breast cancers by measuring activity 
of other enzymes in the same samples. It is possible to measure 
activity of other steroid metabolic pathways in these same 
incubations since the steroid metabolites are extracted into 
chloroform at the end of each incubation and these had been stored 
for further analysis.
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Chapter 6.
17-beta hydroxysteroid dehydrogenase activity 
in breast adipose tissue.
79
Introduction
The results in chapters 3 & 5 suggest an association between
elevated aromatase activity and breast cancer. A possible 
explanation for this phenomenon is that tumours stimulate an 
increase in metabolism in their surrounding tissues. It should be 
possible to determine if there is a general increase in metabolism 
by measuring activity of other enzymes in the same tissue samples.
Preliminary studies on steroid metabolism in adipose tissue
(results not shown) indicated that metabolism of the substrate
androstenedione to products other than oestrogen was occuring in
these incubations. The most substantial metabolite (in terms of
percentage conversion) was testosterone. Such metabolism has been
121 123
noted m  other studies ' . This transformation is mediated
by the 17-beta hydroxysteroid oxidoreductase enzyme(s) usually 
referred to as 17-beta hydroxysteroid dehydrogenase (17BHSD). This 
enzyme has a pivotal role in the interconversion of both androgens 
and oestrogens; transforming the relatively inactive precursors 
androstenedione and oestrone into the more biologically active 
testosterone and oestradiol. Previous studies on this enzyme in 
the breast have shown that levels of activity vary greatly between 
breast tumours, normal breast tissue and adipose tissue^
Since this enzyme could play a key role in modifying the local 
hormonal environment of the breast, it is of interest to study its 
activity in the breast adipose tissue samples.
The activity of this enzyme may be measured simultaneously in the 
tritium release assay since the steroid metabolites (including
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testosterone) were extracted from the incubations into chloroform. 
The majority of these extracts were available for further analysis.
Methods
Chloroform extracts from the incubations of adipose tissue 
(performed as described in Chapters 3 & 5) were retained and stored 
at -20 °C until assayed (45 cancer patients, 32 benign disease). To 
monitor procedural losses, radioinert testosterone (250 ug) was 
added to each sample. Aliquots were taken from each extract for 
determination of the total radioactivity present (by scintillation 
counting) The samples were then evaporated to dryness under a 
continuous stream of nitrogen, reconstituted in 200 ul of ethanol 
and run in 2 consecutive Thin Layer Chromatography systems (ref): 
Chloroform: Acetone 185:15 followed by Benzene: Ethyl Acetate
80:20. This separates testosterone from the other steroid 
metabolites; in particular the radiolabeled androstenedione. The 
testosterone fractions were then characterised by chemical 
derivative formation using the following techniques:-
Acetylation
Acetic anhydride (6 drops) and pyridine (3 drops) were added to the 
dried steroid, which was then incubated at 60 °C for one hour. 
Methanol (1ml) was added and the mixture re-evaporated to dryness. 
The reaction products were then purified by further thin layer 
chromatography (cyclohexane:ethyl acetate 70:30) and the 
testosterone acetate fraction recovered.
Acetate hydrolysis
Testosterone acetate fractions were dried, dissolved in methanol
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(lml) containing 2% Potassium Carbonate (0.25ml) and incubated 
overnight at 37 °C. Distilled water (3ml) was added and the 
steroid extracted into ethyl acetate (5ml x 2) centrifuging to 
partition. The ethyl acetate extracts were then bulked, dried and 
purified by thin layer chromatography (Chloroform: acetone 185:15) 
and the free testosterone recovered.
After the acetylation and hydrolysis reactions the purified
testosterone acetate and testosterone fractions were dissolved in a 
measured volume of ethanol. The radioactivity in a standard aliquot 
was measured by liquid scintillation counting. The quantity of 
recovered steroid was calculated by measuring the optical density 
of the solution at 281nm (Unicam SP800) against known standards. 
(Correction for non-specific absorbance was acheived by subtracting 
the readings from other areas on the tic plate.) The specific
activity was calculated as shown below:
specific activity = _______ dpm in sample_____ (dpm/nmol)
amount of steroid recovered
Purification by thin layer chromatography and chemical derivative
formation continued until three successive specific activities were
consistent to within 10%.
The percentage conversion of androstenedione to testosterone was 
then calculated as shown below:
Percentage = specific activity x cold steroid added (nmol) x 100
conversion total dpm in original sample
Since the specific radioactivity of the androstenedione was known,
the percentage conversion could be converted to pmol and then
expressed as pmol testosterone / mg protein / hour (units).
Results:
Radiolabeled testosterone was detected in all of the extracts 
examined indicating that 17BHSD activity was present in all cases.
)
The individual results are listed in Tables B:3-B:5 (Appendix B). 
Again wide variation in levels of activity has been found between 
individuals (0.03 - 52.8 units) and between the quadrants of
individual breasts (up to six-fold difference between the most and 
least active quadrants). Figure 6:1 compares the activity in breast 
cancer patients with benign disease patients. There is no 
significant difference in levels of activity between cancer 
patients [median 1.4 (0.03 - 52.8) units] and non-cancer patients 
[median 1.0 (0.1 - 10.3) units].
The levels of activity found in the quadrants of the twelve 
mastectomies are shown in Table 6:1 and illustrated diagramatically 
in Figure 6:2. There is no consistent pattern of distribution of 
activity within the breast quadrants (Friedman Test) or in relation 
to tumour site (Wilcoxon signed rank test).
Figure 6:3 shows enzyme activity related to tumour size at the time 
of surgery for all patients and Figure 6:4 for post-menopausal 
women only. In the post-menopausal group there is a significant 
correlation between tumour size and enzyme activity (r = 0.71 p < 
0.01). This relationship does not reach statistical significance 
in the larger group (r =0.25). Nevertheless the trend for higher 
activity to be associated with larger tumours is confirmed (p < 
0.01 by Wilcoxon rank test) if levels of activity around tumours 
greater than 3cm are compared with smaller lesions (Figure 6:5).
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TABLE 6:1. Adipose Tissue 17BHSD Activity in Breast Quadrants 
(Figures in brackets - ratio of activity to lowest activity in that breast)
Patient 17BHSD Activity in Breast Quadrants
LIQ LOQ UIQ UOQ Mean
4. 1.9* 1.6* 1.5 1.7 1.7
(1.3) (1.1) (1) (1.1)
9. 1.9 1.2 3.6* 0.7 1.9
(2.7) (1.7) (5.1) (1)
11. 0.06 0.07 0.07 0.07* 0.07
(1) (1.2) (1.2) (1.2)
14. 0.57 0.9 0.47 0.5* 0.6
(1.2) (1.9) (1) (1.1)
15. 0.4 1.7* 0.5 0.5* 0.8
(1) (4.3) (1.3) (1.3)
18. 0.56 0.7 0.9* 0.87* 0.8
(1) (1.2) (1.6) (1.5)
23. 4.13 4.18 5.8 4.1* 4.6
(1) (1) (1.4) (1)
26. 0.07 0.08 0.03 0.06* 0.06
(2.3) (2.7) (1) (2.0)
33. 0.04 0.05*+ C.04*+ 0.07*+ 0.05
(1) (1.3) (1) (1.8)
34. 2.0 3.7 2.2 1.9* 2.5
(1.1) (1.9) (1.2) (1)
39. 0.37 0.39 0.36 0.3* 0.36
(1.2) (1.3) (1.2) (1) .
47. 4.3 1.2+ 2.3 6.6* 3.6
(3.6) (1) (1.9) (5.5)
* Quadrant containing clinically detected tumour 
+ Additional tumour foci discovered on histology
LIQ - Lower Inner Quadrant LOQ - Lower Outer Quadrant 
UIQ - Upper Inner Quadrant UOQ - Upper Outer Quadrant
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Figure 6:6 relates levels of activity to the presence or absence of 
nodal metastases for the 41 patients who had axillary staging 
performed (minimum of 4 nodes examined). Activity is
significantly higher in those patients with nodal metastases (n = 
17, median 2.1 units) compared to node negative patients (n = 24, 
median 0.8 units, p < 0.01).
Figures 6:7-6:10 show levels of activity plotted against age, 
obesity, parity (parous v nulliparous) and menopausal status 
showing that there is no apparent relationship between activity and 
any of these factors.
Analysis of results in relation to patient height, weight and
family history of breast cancer also failed to reveal any
significant correlation (results not shown).
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Discussion
This study confirms that all samples of breast adipose tissue 
possess 17BHSD activity with levels varying markedly between 
individuals. Levels of activity are generally higher than levels 
of aromatase in the same specimens (in only one case was the 
conversion of androstenedione to testosterone lower than the 
conversion to oestrogen). This finding and the levels of activity 
observed in these specimens are consistent with the results of 
other studies10'121'123.
The fact that there is no significant difference in levels of 
activity between the breast cancer patients and those with benign 
disease is also in keeping with the earlier report of Beranek et
Levels of activity also vary between the quadrants of the twelve 
breasts studied, but with no consistent pattern of activity between 
the quadrants or in relation to the location of tumours in the 
breasts. In contrast to the distribution of aromatase activity 
higher activity is not associated with the upper outer quadrant (in 
seven cases activity was greater in the lower inner quadrant than 
in the upper outer quadrant). There is therefore no evidence from 
this study to support the suggestion by Beranek et al. that low 
levels of activity are found in the lower half of the breast11. 
This suggestion, however, was based on results from only four 
samples from lower breast quadrants with no samples being obtained 
from other quadrants of the same breast for comparison.
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In contrast with the earlier results for aromatase activity, 17BHSD 
is not elevated in cancerous breasts or in tumour-bearing 
quadrants. It therefore seems unlikely that there is a 
non-specific increase in steroid metabolism around breast cancers.
The association between levels of 17BHSD activity and tumour size 
is interesting and has been observed previously^. A possible 
explanation for this phenomenon is that tumours can produce factors 
which stimulate 17BHSD activity in their surrounding tissues and 
that larger tumours would be expected to produce more of an effect. 
However in the majority of the mastectomy specimens studied higher 
levels of activity were detected in areas remote from the tumours. 
While this does not preclude an effect of tumours on enzyme 
activity, there must be other factors influencing enzyme activity 
in the breast. The association of elevated enzyme activity with 
large tumours may therefore not be entirely due to enhancement of 
local enzyme activity by these tumours.
It is possible, however, that locally enhanced enzyme activity
could stimulate tumour growth by producing a local increase in the
concentration of oestradiol. In keeping with this suggestion a
number of studies have reported elevated concentrations of
14 51 99
oestradiol in tumours and their surrounding tissues ' ' . These
two explanations are not mutually exclusive and it is possible that 
some tumours may stimulate their own growth by increasing levels of 
17BHSD in their immediate surroundings in order to increase the 
local concentration of growth promoting hormones.
The fact that higher levels of activity are also seen around
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tumours that have metastasised to regional lymph nodes is
consistent with elevated enzyme activity being associated with more 
rapidly growing (and disseminating) tumours.
The present study fails to show any correlation between levels of
17BHSD and parity, menopausal status, weight or obesity. Although
there have been no reports on the 17-beta hydroxy reduction of
androstenedione being influenced by any of these factors, Beranek
et al found that the rate of oestrone 17-beta hydroxy reduction was
9
positively correlated with body weight and Deslypere et al
suggested that the oxidation of oestradiol was greater in
37
premenopausal women . Other studies, however fail to confirm 
these associations'^
In conclusion, therefore there is no evidence for a non-specific 
increase in aromatase and 17BHSD activity around breast cancers. 
Levels of 17BHSD activity in adipose tissue however, appear to be 
related to tumour size and the presence of lymph node metastases.
The possibility that tumours can influence levels of specific 
enzymes in their surrounding tissues cannot be excluded.
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Chapter 7.
Enzyme activity in adipose tissue immediately adjacent to tumours.
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Introduction
If the relationships between enzyme activities and breast cancer 
seen in the earlier studies reflects specific tumour enhancement of 
enzyme activity in their surrounding tissues then a gradient of 
activity should be detectable in surrounding tissues with higher 
activity in the immediate vicinity of the tumour. The aim of this 
study was therefore to investigate aromatase and 17BHSD activity in 
tissue from the immediate vicinity of tumours and compare these 
with the activities in samples from the same breast quadrant but 
which are more remote from the tumour.
Methods:
Adipose tissue samples were obtained from the immediate vicinity of
9 tumours and also from within the same quadrant but more remote
from the tumour. In a further case two tumours were present in the
same breast. Samples were therefore obtained from the vicinity of
both of these tumours and from an intermediate area of the breast.
These samples were then processed as before and incubated with 
3
1-beta H androstenedione to measure both aromatase and 17BHSD 
activity.
Results:
The results of the aromatase assays are shown in Table 7:1. 
Aromatase activity was higher in the immediate vicinity of 6 of the 
tumours but lower in the other 5. The results of the 17BHSD assays 
are shown in Table 7:2. Activity was higher in the immediate 
vicinity of only 4 of the tumours, with lower activity in the 
remaining 7.
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Table 7:1.
Aromatase activity in adipose tissue adjacent to and remote from tumours,
No. SITE ADIPOSE
TISSUE
(GM)
PROTEIN
CONC
(mg/ml)
AROMATASE
%CONV.
AROMATASE 
fmol/mg prot 
/hour
1 ADJ 1 1 1.1 .019 11.5
ADJ 2 1.1 1.7 .046 18.0
REM 0.8 0.9 .033 24.4
3 ADJ 1.1 1.2 .132 70.4
REM 1 1.1 .033 20
6 ADJ 2 2.9 .128 29.4
REM 2 2.2 .011 3.3
12 ADJ 2 2.0 .033 11
REM 2 1.8 .021 7.8
14 ADJ 1.9 1.0 .017 11.3
REM 2 2.5 .12 32
15 ADJ 1.3 3.7 .099 17.8
REM 2 6.0 .315 35
32 ADJ 2 2.1 .055 17.5
REM 2 1.6 .053 22.1
39 ADJ 2 1.9 .044 15.4
REM 1.2 3.4 .064 12.6
46 ADJ 1.6 1.4 .046 21.9
REM 2 1.8 .022 8.1
48 ADJ 1 2.3 .070 20.3
REM 1 0.7 .038 36.2
49 ADJ 2 2.2 .067 20.3
REM 2 3.0 .035 7.8
Table 7:2.
17BHSD activity in adipose tissue 
adjacent to and remote from tumours.
No. SITE ADIPOSE
TISSUE
(GM)
PROTEIN
CONC
(mg/ml)
17BHSD
%CONV
17BHS1 
pmol/mg ] 
/hour
1 ADJ 1 1 1.1 2.4 1.44
ADJ 2 1.1 1.7 9.1 3.56
REM 0.8 0.9 2.63 1.95
3 ADJ 1.1 1.2 3.93 2.1
REM 1 1.1 1.35 0.8
6 , ADJ 2 2.9 12.6 2.9
REM 2 2.2 13.8 4.2
12 ADJ 2 2.0 4.34 1.4
REM 2 1.8 2.18 0.8
14 ADJ 1.9 1.0 1.6 0.4
REM 2 2.5 1.4 0.5
15 ADJ 1.3 3.7 3.0 0.5
REM 2 6.0 14.9 1.7
39 ADJ 2 1.9 0.2 0.06
REM 1.2 3.4 1.6 0.3
46 ADJ 1.6 1.4 16.4 7.8
REM 2 1.8 24.3 9.0
48 ADJ 1 2.3 3.5 1.0
REM 1 0.7 2.4 2.3
49 ADJ 2 2.2 0.86 0.26
REM 2 3.0 0.92 0.20
Analysis of the results in relation to tumour type fails to 
indicate that certain tumour types are associated with enhanced 
enzyme activity. In addition there does not appear to be any 
correlation between the results for the two different enzymes.
Conclusion:
These results again highlight the wide variations in enzyme 
activity that occur within the breast. There is however no 
evidence for a zone of high aromatase or 17BHSD activity 
immediately around all tumours. It therefore seems unlikely that 
the earlier association of aromatase activity with breast cancer is 
entirely due to tumour enhancement of activity. The possibility 
still remains that some tumours may be capable of stimulating 
activity in their surroundings while others may be capable of 
inhibiting activity.
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Chapter 8.
Steroid metabolism in breast adipose tissue of treated breast
cancer patients.
91
Introduction
The results presented in the earlier chapters suggest that steroid 
metabolism in breast adipose tissue may be involved in the 
evolution and continued growth of breast cancers. It is therefore 
possible that such local metabolism might influence the response of 
a cancer to systemic treatment. The purpose of this study was 
therefore to determine if levels of enzyme activity in breast 
adipose tissue are influenced by systemic therapy or correlate with 
the response to treatment.
Methods
Twenty-two of the breast cancer patients included in the earlier 
studies had received either local or systemic treatment prior to 
mastectomy. Details of the treatments given are outlined in Table 
8:1 .
In seventeen patients treatment was administered prior to surgery
in an attempt to reduce tumour size and determine the sensitivity
of the primary tumours to systemic therapy. Details of patient
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selection and the modes of therapy are described elsewhere . Seven 
patients received tamoxifen, three aminoglutethimide with 
hydrocortisone and three had an oophorectomy. Four of these who 
failed to respond to such endocrine therapy (oophorectomy n = 2 ; 
Tamoxifen n = 1; Aminoglutethimide n = 1) went on to have 
chemotherapy. A further four patients had chemotherapy alone. 
Treatment continued for three months and clinical response was 
monitored as accurately as possible by mammography and clinical 
examination. After treatment a mastectomy was performed. Response 
was considered complete if there was clinical resolution of the
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Table 8:1.
Details of patients who received local or systemic therapy prior to 
mastectomy. Tumour size = pathologist's measurement. Size in brackets is 
the initial clinical measurement.
Patient
Mo.
Type of Carcinoma Treatment Tumour 
Size (cm)
2 No special type Tam. > PR 2.0 (4.5)
9 Lobular Tam. no response 6.0
10 Ductal oox. no response, CHOP > PR 2.0 (5.8)
12 Mucoid WLE + R/TH > recurrence 1.5
14 Adenocarcinoma AMG > PR 2.6 (5.2)
16 Mucoid Oox > PR 2.0 (5.0)
17 Ductal Tam > PR 2.5 (4.0)
18 Lobular CHOP (defaulted) 4.0 (5.2)
22 No special type CHOP + R/TH + boost 5.0
23 Ductal Tam > progression 4.5 (3.2)
26 Adenocarcinoma CHOP > CR 0 (10.0)
28 No special type CHOP > CR o ■ (3.0)
30 Ductal AMG >Prog. Dis.>CHOP >CR 0 (4.2)
31 Ductal Tam >Prog. Dis.>CHOP >PR 2.0 (4.5)
33 No special type R/TH for in situ carcinoma 5.0
36 No special type CHOP > PR 1.5 (6.2)
40 Ductal AMG (stopped - reaction) 5.0
42 Ductal AMG > PR 2.0 (5.2)
43 Ductal Tam > PR 1.8 (4.3)
45 Atypical Medullary Oox >no response >CHOP >PR 3.0 (5.2)
47 Spindle Cell CHOP > no response 3.7
51 Ductal WLE + CMF > local recurrence 3.8
Tam. - Tamoxifen; Oox - oophorectomy; AMG - aminoglutethimide; 
CHOP - Cyclophosphamide, doxorubicin, vincristine + prednisolone; 
R/TH - Radiotherapy; WLE - wide local excision of breast cancer; 
CMF - Cyclophosphamide, methotrexate + 5 fluorouracil;
CR - complete response; PR - partial response
tumour with no histologically detectable tumour at mastectomy. A 
partial response was indicated by a reduction in tumour size, with 
tumour still detectable at mastectomy. Absence of tumour
regression indicated a failure of response. Samples of breast 
adipose tissue were obtained at the time of mastectomy (if complete 
tumour regression had occured, tissue was taken from the area 
around the site of the resolved tumour).
Adipose tissue was also obtained from one patient (No. 18) who 
failed to complete a full course of chemotherapy and another (No. 
40) who had to discontinue treatment with aminoglutethimide 
because of an adverse reaction. These patients could therefore not 
be adequately assessed for response.
Tissue samples were obtained at the time of mastectomy from a 
further three patients who developed local recurrence following 
wide local excision of small tumours. Two of these patients (Nos. 
12,33) had received post-operative radiotherapy, the other (No. 51) 
received adjuvant chemotherapy. Tissue was also obtained from a 
patient (No. 22) who presented with a locally advanced tumour (T4). 
This tumour responded to a combination of chemotherapy and 
radiotherapy and was then treated by mastectomy.
In all patients, adipose tissue was obtained at the time of 
mastectomy, i.e. after local or systemic therapy. Assays of 
aromatase and 17BHSD activity in the adipose tissue samples from 
these patients were performed as part of the earlier experiments 
(Chapters 3 & 6). In one case (No. 2) aromatase activity alone was 
measured.
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Results:
The results of the aromatase and 17BHSD assays on breast adipose 
tissue from these patients are shown in Table 8:2. Aromatase and 
17BHSD activities are subdivided according to the type of therapy 
in Figures 8:1 and 8:2. The median levels of activity for each
enzyme are indicated on the figures. Because of the small number 
of patients in each subgroup, valid statistical analysis is not 
feasible. Certain observations can however be made.
All three patients who were treated by oophorectomy have aromatase 
activity which is higher than the median. In contrast only one of 
the six patients treated with tamoxifen had aromatase activity 
greater than the median. It is therefore possible that 
oophorectomy may enhance peripheral aromatase activity while 
tamoxifen may inhibit activity. Neither aminoglutethimide nor 
chemotherapy appear to be associated with particularly high or low 
aromatase activity. None of the therapies are associated with 
either high or low 17BHSD activity.
Activity of both enzymes is low in the two patients who received 
adjuvant radiotherapy, whereas there is high activity of both 
enzymes in the patient who received therapeutic radiotherapy. 
Radiotherapy is known to affect tissues by producing an initial 
inflammatory response with an increase in cellularity. Resolution 
of these changes results in decreased cellularity with an increase 
in fibrous tissue. Although no firm conclusion can be drawn from 
only three patients, the observed results are consistent with
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Table 8:2.
Assay results for patients who received systemic therapy prior to surgery.
NO. Treatment AROMATASE AROMATASE 
%conv. fmol/mg 
/hour
17BHSD
%conv
17BHSD
pmol/mg
/hour
2 Tam. > resp .073 27 - -
9 Tam. no resp .067 34.9 7.0 3.6
10 oox. no resp, CHOP > resp .179 114 1.4 0.9
12 WLE + R/TH > Mx .033 11 4.3 1.4
14 AMG > resp .12 32 1.4 0.5
16 Oox > resp .163 63.5 2.1 0.8
17 Tam > resp .075 18.5 4.1 1.0
18 CHOP (defaulted) > Mx .021 10.8 1.8 0.9
22 CHOP + R/TH + boost > MX + Cl .066 78.6 38 52.8
23 Tam > progression .078 23.7 13.8 4.1
26 CHOP > Comp. Resp .039 14 0.18 0.06
28 CHOP > Comp. Resp .165 44 3.0 0.8
30 AMG >Prog. Dis.>CHOP >Comp R .036 9.2 1.2 0.3
31 Tam >Prog. Dis.>CHOP >PR .046 26.9 1.1 0.8
33 R/TH for in situ > recur > Mx .050 14 0.16 0.04
36 CHOP > resp .08 88.8 10 11.1
40 Mx + Cl (AMG stopped) .024 22.2 3.4 3.3
42 AMG > resp .047 36.4 1.7 1.3
43 Tam > resp .015 6.7 1.0 0.6
45 Oox >no resp >Chop >resp .272 56.7 9.0 1.9
47 CHOP > no resp .122 17.3 19.7 6.55
51 Cons surg CMF > local recur. .093 41.3 9.2 4.1
Abbreviations: see Table 8:1.
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17J3HSD ac t i v i t y  in b r e a s t  adipose tissue 
and previous t h e r a p y
The broken line indicates the median level of activity
for this group of patients.
radiotherapy influencing local metabolism by an effect on 
cellularity. In view of this possibility, and the fact that two of 
the patients received adjuvant radiotherapy and therefore could not 
be assessed for their initial response to treatment it was decided 
to exclude the irradiated patients from analysis of enzyme activity 
in relation to treatment response.
The two patients who did not complete courses of treatment were not 
assessed for response and were therefore excluded from further 
analysis.
Of the seventeen remaining patients there were three complete 
responses and ten partial responses. Four patients failed to 
respond. The four patients who received chemotherapy after failing 
to respond to hormonal manipulations all responded to chemotherapy. 
Tissue samples were only obtained from these patients after 
completion of chemotherapy. Details of the responses to treatment 
are outlined in Table 8:1. The relationship between aromatase 
activity and response is shown in Figure 8:3. Similar analysis of 
17BHSD activity is shown in Figure 8:4. There is no apparent 
relationship between levels of aromatase activity and response to 
treatment. Significantly higher 17BHSD activity however, was found 
in non-responders (median 4.1 units) than in responders (median 0.8 
units) [p < 0.02 by Wilcoxon rank test]. The lowest levels of 
activity were found in patients with complete responses (median 0.3 
units). Only one of the twelve patients who responded to 
treatment had activity > 2.0 units, whereas the lowest activity
detected in a non-responder was 3.6 units.
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Activity of both enzymes is plotted against tumour size in Figures 
8:5 and 8:6. There is no statistically significant correlation 
between activity of either enzyme and tumour size, (aromatase vs 
size, r = -0.09, 17BHSD vs size, r = 0.31 p = NS).
Analysis of enzyme activity in relation to the responses to the 
individual treatments is again difficult because of the small 
numbers in each subgroup and the fact that four patients received 
both hormonal and chemotherapy. Figures 8:7-8:10 compare aromatase 
and 17BHSD activity with the responses to the various treatments 
used.
Response to tamoxifen, oophorectomy or chemotherapy appears to be 
associated with relatively low 17BHSD activity. The patients who 
responded to aminoglutethimide had higher levels of both aromatase 
and 17BHSD activity than the patient who failed to respond. Two of 
the three patients who responded to tamoxifen had lower levels of 
aromatase activity than the patients who failed to respond.
Discussion
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Forrest has recently suggested that the response of breast 
tumours to systemic treatment may be determined by the biochemical 
features of the tumour. There have been no previous reports 
suggesting that steroid metabolism in the tissues surrounding
tumours may also be important.
With the variety of therapies used in these patients, only small 
numbers of patients received any one therapy. No firm conclusions
can be reached on the role of local steroid metabolism in
L
r
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the response to particular therapies. In addition, since samples 
of tissue were only obtained after treatment it is uncertain 
whether the treatment or the response of the tumours to treatment 
has influenced levels of activity. There are however, certain 
interesting trends.
With the possible exception of radiotherapy, there is no evidence 
to suggest that any of the treatments consistently enhance or 
inhibit peripheral 17BHSD activity. The results from the 
irradiated patients are consistent with radiotherapy initially 
stimulating activity but later leading to decreased activity.
Aromatase activity in adipose tissue is high in the three patients
treated by oophorectomy. This is of interest in view of the
earlier finding of high aromatase activity in perimenopausal women
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(Chapter 3). Folkerd has also noted enhanced aromatase activity
in adipose tissue from peri-menopausal women and has suggested that
peripheral aromatase activity could be stimulated by high levels of
FSH. If this is the case, then it must only be a temporary effect
since there is no evidence from the earlier studies (Chapter 3) or 
10 37
those of others ' , to indicate that activity is higher in
postmenopausal women, who have high levels of FSH.
The observation of relatively low aromatase activity in patients
treated by tamoxifen with the lowest levels being seen in the
patients who responded to this treatment is also interesting.
Perhaps tamoxifen reduces local production of oestrogen in
addition to preventing oestrogen from binding to the oestrogen 
153
receptor . An alternative explanation is that anti-oestrogen
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therapy is more likely to be effective in patients with reduced 
levels of local oestrogen production.
78
Aminoglutethimide is an aromatase inhibitor and should therefore
be effective against tumours which rely on oestrogen biosynthesis
for their continued growth. It is therefore of interest that the
patients who responded to aminoglutethimide had higher levels of
aromatase activity than the patient who failed to respond.
Whether such aromatase activity in adipose tissue is crucial for
tumour growth or merely indicates the capacity of that patient's
tissues to synthesize oestrogen remains to be determined. Another
explanation, however, is that aminoglutethimide enhances peripheral
aromatase activity. Such a phenomenon has been observed in breast 
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tumours . The fact that levels of aromatase activity in these 
patients were not higher than those observed in untreated patients 
makes such an explanation seem unconvincing.
The relationship between 17BHSD activity and response to all modes 
of treatment is striking. Higher levels of activity are associated 
with failure to respond, whereas lower levels are found in those 
who responded to therapy. There are a number of possible 
interpretations of this phenomenon. This could be a further 
manifestation of the relationship between 17BHSD activity and 
tumour size. Although the relationship between 17BHSD activity and 
tumour size at the time of surgery is not statistically 
significant, there is once again a trend for the highest levels of 
enzyme activity to be associated with the larger tumours. At the 
time of surgery the tumours which had responded to treatment were 
small and were associated with lower levels of 17BHSD than the 
larger tumours which failed to respond. Such an explanation implies
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that local levels of 17BHSD are determined by the tumour; with 
levels of activity falling as tumours regress. If tumour growth is 
enhanced by locally elevated enzyme activity, these tumours, which 
were initally large, should have been associated with high enzyme 
activity. Investigation of levels of activity before and after 
treatment is necessary to determine whether levels of enzyme 
activity fall as tumours respond to therapy.
An alternative explanation is that enhanced local 17BHSD activity 
may be associated with tumours which are resistant to systemic 
therapy whereas low activity is found around tumours that will 
respond to therapy. If this is the case, then measurement of 
local enzyme activity could provide an important guide to the 
likely therapeutic response of a tumour.
While there are insufficient numbers of patients in the present 
study to permit firm conclusions on the role of local steroid 
metabolism in the progression or regression of breast tumours, the 
results are consistent with local steroid metabolism being involved 
in the response of tumours to therapy, implying that modification 
of local steroid metabolism could influence the outcome of the 
disease. Information on levels of enzyme activity before and after 
treatment in a larger series of patients should help to clarify the 
situation.
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Chapter 9.
Steroid metabolism and the fatty acid composition of breast adipose
tissue.
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Introduction
The foregoing studies, and those of
others10'14'37'55'57'115'121'122'123, have revealed that
substantial individual variation occurs in levels of both aromatase
and 17BHSD activity in breast adipose tissue. The factors which
influence levels of activity and could account for such variation
29 87 103
have been the subject of of considerable investigation ' '
■j r 7 /“ o*7
In vitro experiments indicate that androgens ' ' ,
12 68 129
progestogens ' ' , epidermal growth factor and transforming
growth factor a l p h a c a n  alter 17BHSD activity, and one report
fin
has shown that progesterone enhances activity in vivo . Various 
substances, including corticosteroids, cyclic AMP, methyl xanthines 
and prolactin are known to influence aromatase activity in 
v i t r o ^ ' ^ ' ’^ ' " ^ ' ' ^ ,  but to date there is little evidence that 
any of these factors operate in vivo.
It has been suggested that a high fat diet may increase oestrogen
•j r r
biosynthesis in adipose tissue . Experiments have shown that
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changes in dietary fat can alter plasma hormone levels , and
80
influence the menstrual cycle . Since the composition of the 
diet determines the fatty acid composition of adipose 
t i s s u e ^ ' i t  is not unreasonable to suggest that dietary 
fat could influence metabolism in adipose tissue.
Aim:
To measure the relative proportions of the fatty acids present in 
breast adipose tissue and to correlate levels with the aromatase 
and 17BHSD activity in these samples.
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Methods
Tissue samples:
Stored samples of adipose tissue from 10 of the patients studied 
earlier were analysed for fatty acid content. Samples were chosen 
to include a wide range of enzyme activities and, in two cases, 
samples from different breast quadrants with differing enzyme 
activities.
Analysis of fatty acids.
(The analyses were kindly performed by Dr Rudolph A Riemersma, 
Senior Lecturer, Department of Cadiovascular Research, Edinburgh 
University.) Details of the methodology have been described 
elsewhere . Lipids were extracted into redistilled heptane, and 
the extract was washed with isopropanol/0.05% potassium hydroxide 
by volume, to remove non-esterified fatty acids and phospholipids. 
The neutral lipid extract was reduced to dryness under vacuum then 
dissolved in dry toluene. Fatty acid methyl esters were prepared 
by direct transmethylation (10 min. at 50°C, with 0.5 mol/1 sodium 
methoxide in methanol). The fatty-acid esters were washed with 
acidified water and re-extracted into hexane; the hexane layer was 
evaporated under vacuum. The methyl esters were redissolved in 
40ul redistilled chloroform, ready for analysis on a Pye 
Chromatograph 204, fitted with a 1.5 m column, packed with GP 10% 
SP-2330 on 100/120 mesh 'Chromosorb W A W 1 (Supelco). The peaks were 
quantified with a flame ionisation detector and 'Tri-Vector III1 
integrator. The methyl-ester peaks in the chromatograms were 
identified by a combination of argentation thin layer 
chromatography and comparison of retention times with those of 
authentic fatty-acid methyl esters (Pufa 1 and 2 and NIH mixtures,
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Supelco). For complex peaks, gas chromatography/mass 
spectrophotometry was used in a few random samples. All these 
methods showed that the methyl esters of eicosanoic acid (20:0 ) and 
gamma-1inoleic acid (18:3 n-6 ) coincide, as do those of eicosaenoic 
acid (20:1 n-9) and alpha-linolenic acid (18:3 n-3). The relative 
amounts of the constituents in these complex peaks were not 
determined. The coefficient of variation in determining the
percentages of the individual fatty acids changed with the level 
measured. It was between 0.9% and 4.4% for the major components 
(palmitic, palmitoleic, oleic and linoleic acids), whereas the 
error for trace constituents (less than 1%) was about 17.5%.
Statistics
Analysis of the results was performed by calculation of Spearman's 
linear correlation coefficients.
Results:
The results of the fatty acid analyses are expressed as a
percentage of the total fatty acids. The majority of these are 
listed in Table 9:1 in ascending order of 17BHSD activity and 
similarly in Table 9:2 with the aromatase activities. Correlation 
coefficients were calculated between enzyme activities and the 
individual fatty acids, the ratio of polyunsaturated to saturated 
fatty acids (P/S ratio) and the total level of n-6 polyunsaturated 
fatty acids (total n-6, see below) in each sample.
Significant inverse correlations were noted between 17BHSD activity 
and the P/S ratio (r = -0.73, p < 0.01 ); linoleic acid (r = -0.65
p < 0.05 ); total n-6 (r = -0.63, p < 0.05 ); and eicosaenoic acid
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TABLE 9:1.
FATTY ACID COMPOSITION AND 17BHSD ACTIVITY IN BREAST ADIPOSE TISSUE.
Patient
17BHSD
paol/ag
prot/hr 14:0 16:0 18:0 18:1
Fatty Acid concentrations (X) 
18:2 20:0 20:1 20:2 20:3 20:4 22:4 F7S ratio
15 UIQ 0.5 4.3 19.5 5.7 46.1 9.4 .40 4.1 .07 .16 .81. .08 .35
15 L09 0.5 4.5 19.8 6.0 45.9 9.2 .41 4.2 .07 .16 .83 .08 .34
43 0.6 3.8 22.8 4.9 47.2 9.5 .17 3.0 .19 .22 .56 .17 .35
13 0.7 2.8 23.0 5.5 48.1 S.l .18 2.9 .20 .14 .57 .15 .30
9 UQQ 0.7 4.2 22.1 7.0 47.0 6.7 .19 3.5 .20 .08 .51 .12 .23
54 0.9 3.5 21.0 5.9 46.3 10.4 .18 3.3 .22 .16 .62 .17 .39
19 1.3 4.2 21.7 6.8 44.5 11.3 .26 3.1 .19 .14 .44 .08 .37
29(ben) 1.5 4.2 20.6 8.6 45.6 10.3 .28 3.0 .13 .14 .52 .08 .33
37 3.5 2.8 21.5 3.1 50.6 7.5 .08 2.9 .19 .20 .48 .25 .32
9 UIQ 3.5 3.9 22.6 5.6 48.3 7.0 .13 3.0 .03 .11 .44 .13 .25
6 4.2 4.6 22.5 6.5 46.7 7.4 .17 2.7 .13 .14 .49 .11 .25
33 tben) 10.3 4.7 26.0 6.7 44.4 6.2 .14 2.4 .16 .24 .64 .24 .21
FATTY ACIDS - 14:0 ayristic 18:1 oleic 20:1 gadoleic 20:4 arachidonic
16:0 palsitic 18:2 linoleic 20:2 eicosadienoic 22:4 docosatetraenoic
18:0 stearic 20:0 behenic 20:3 dihono-V-1inolenic
P/S ratio - ratio of total polyunsaturated to saturated fatty acids
(ben) - patient Kith benign breast disease
U09,UI8,L08 - adipose tissue froa upper outer, upper inner, or lower inner breast quadrant.
TABLE 9:2.
FATTY ACID COMPOSITION AND AROMATASE ACTIVITY IN BREAST ADIPOSE TISSUE.
Patient
No.
Arosatase
fsiol/ag
prot/hr 14:0 16:0 18:0 18:1
Fatty Acid concentrations (X) 
18:2 20:0 20:1 20:2 20:3 20:4 22:4 P/S ratio
33(ben) 3.1 4.7 26.0 6.7 44.4 6.2 .14 2.4 .16 .24 .64 .24 .21
6 3.3 4.6 22.5 6.5 46.7 7.4 .17 2.7 .13 .14 .49 .11 .25
43 6.7 3.8 22.8 4.9 47.2 9.5 .17 3.0 .19 .22 .56. .17 .35
15 UIQ 10.5 4.3 19.5 5.7 46.1 9.4 .40 4.1 .07 .16 .81 .08 .35
29(ben) 11 4.2 20.6 8.6 45.6 10.3 .28 3.0 .13 .14 .52 .08 .33
9 U0Q 12.2 4.2 22.1 7.0 47.0 6.7 .19 3.5 .20 .08 .51 .12 .23
37 14 2.8 21.5 3.1 50.6 7.5 .08 2.9 .19 .20 .48 .25 .32
13 16.4 2.8 23.0 5.5 48.1 8.1 .18 2.9 .20 .14 .57 .15 .30
19 34.2 4.2 21.7 6.3 44.5 11.3 .26 3.1 .1? .14 .44 .03 .37
9 U18 34.9 3.9 22.6 5.6 48.3 7.0 .13 3.0 .03 .11 .44 .13 .25
15 L08 35 4.5 19.8 6.0 45.9 9.2 .41 4.2 .07 .16 .83 .03 .34
54 40.9 3.5 21.0 5.9 46.3 10.4 .18 3.3 .22 .16 .62 .17 .39
FATTY ACIDS - 14:0 ayristic 18:1 oleic 20:1 gadoleic 20:4 arachidonic
16:0 palsitic 18:2 linoleic 20:2 eicosadienoic 22:4 docosatetraenoic
18:0 stearic 20:0 behenic 20:3 dihoao-9-1inolenic
P/S ratio - ratio of total polyunsaturated to saturated fatty acids
(ben) - patient with benign breast disease
1)09,1)18,LOS - adipose tissue froa upper outer, upper inner, or lower inner breast quadrant.
(r = 0.61, p < 0.05 ). These are illustrated in Figures 9:l-9:4. 
The same correlations are evident whether the enzyme activity is 
expressed as % conversion or as pmol/mg prot/hr. No other 
correlations reached statistical significance. There was no 
correlation between aromatase activity and any of the parameters. 
An example of the aromatase results is shown in Figure 9:5 where 
activity is plotted against linoleic acid concentration.
Discussion
These results suggest a relationship between levels of 
polyunsaturated fatty acids in breast adipose tissue and 17BHSD 
activity. Since fatty acids in adipose tissue reflect the fatty 
acid composition of the d i e t ^ ' ^ ' ' ^ ,  this implies that dietary 
fat could have a direct or indirect influence on 17BHSD. It is 
also possible, however that the two parameters are coincidentally 
related by another mechanism.
Dietary polyunsaturated fatty acids are required for the normal
function of all tissues. Of the polyunsaturated fatty acids in the
5 6
diet, linoleic acid is quantitatively most significant 
Although humans are able to synthesize many fatty acids from the 
saturated fats in the diet double bonds cannot be introduced into 
the n-3 and n-6 positions of the carbon chains. Humans are 
therefore unable to synthesize linoleic acid (18:2 n-6 ) or
linolenic acid (18:3 n-3), which must be obtained from diet sources 
and are referred to as essential fatty acids. Further metabolism 
of these essential fatty acids produces two families (the n-3 and 
n-6) of essential fatty acids which are required for cell 
structures and prostaglandin synthesis^'
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Adipose tissue a r o m atase activ i t y  
and linoleic acid concentration.
Since linoleic acid in the diet is present in much greater quantity 
than any of the other polyunsaturated fatty acids, and is also the 
precursor of the n-6 series of fatty acids, the total 
polyunsaturated fatty acids, the P/S ratio, and the total n-6 for 
each sample are largely a reflection of the level of linoleic acid. 
The correlations between these parameters and 17BHSD may therefore 
be simply a reflection of the correlation with linoleic acid. 
Linoleic acid however has no influence on the level of eicosaenoic 
acid (20:1 n-9)^, levels of which also correlate inversely with 
17BHSD.
There are a number of possible explanations for the observed
relationships. Levels of fat in the diet can significantly effect
cellular metabolism by altering levels of cytochromes in the
117
endoplasmic reticulum . Such changes could influence 17BHSD 
activity by altering the synthesis of the enzyme and/or essential 
cofactors.
Alternatively polyunsaturated fatty acids could have an indirect
effect on enzyme activity by modifying the pathways which control
enzyme expression. As mentioned above, 17BHSD activity in adipose
tissue and in breast epithelial cells appears to be influenced by
androgens, progesterone, Epidermal Growth Factor and Transforming
Growth Factor alpha. Free fatty acids are known to influence the
23
availability of steroid hormones for biological activity . Levels 
of free fatty acids in adipose tissue might therefore modify the 
effect of androgens and progesterone on 17BHSD activity. Epidermal 
Growth Factor and Transforming Growth Factor alpha act via cell
105
93
membrane receptors . Since polyunsaturated fatty acids are
56
essential components of cell membrane phospholipids , subtle 
changes in the fatty acid composition of these phospholipids could 
have considerable influence on the regulation of membrane 
receptors^ and subsequent signal transduction mechanisms^ 
thereby modifying the effect of growth factors on 17BHSD activity.
The earlier studies indicated that enhanced levels of 17BHSD were 
found around large tumours. Perhaps the observed association is 
not specifically between fatty acids and 17BHSD, but between fatty 
acids and large tumours. This explanation seems unlikely since two 
of the samples came from women with benign breast disease and a 
further two samples were from breast quadrants which did not 
contain tumours. For the other eight samples there is no 
significant relationship between tumour size and the fatty acid 
levels. Nevertheless tumours require essential fatty acids for 
cell membrane synthesis and for the maintenance of normal membrane
1 cc
function . It has been suggested that a significant proportion 
of the lipid incorporated into tumours is derived from, surrounding 
adipose tissue . Large tumours are therefore likely to absorb 
essential fatty acids from their surrounding tissues, and this 
could result in lower levels of essential fatty acids in the 
adipose tissue around these tumours. Such a mechanism could 
contribute to the association between high 17BHSD activity and low 
levels of essential fatty acids.
Animal experiments suggest that polyunsaturated fatty acids
stimulate tumour growth by providing the precursors for 
25
prostaglandins , which have been implicated as important local
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growth factors in mammary tumour cells ' . At present there is no 
evidence that prostaglandins directly influence 17BHSD but they 
could play a role in regulation of the enzyme.
The absence of any correlation between fatty acid levels and
aromatase activity suggests that dietary fat does not influence
this enzyme system. This study, however, has only considered the
relative proportions of the various fatty acids in adipose tissue.
It is possible that the composition of membrane phospholipids or
the total amount of fat in the diet could be important factors.
High fat diets are known to increase tissue levels of Cytochrome 
117
p450 which is a prosthetic group for the aromatase complex 
and could be crucial in determining activity in vivo. 
Further studies are required before any firm conclusion can be 
reached on the influence of dietary fat on aromatase activity.
Nevertheless, the interesting correlations between fatty acids and 
17BHSD activity suggest that dietary fat could influence some 
aspects of steroid metabolism in breast adipose tissue.
107
Chapter 10
Discussion of the relevance of steroid metabolism in breast adipose
tissue.
108
The role which steroid hcrnor.es play in the natural history of
breast cancer is a problem which has attracted the attention of
research investigators for many years. Oestrogens have come under
particular scrutiny since there is indirect evidence that
altered oestrogen exposure may influence the incidence of the
disease; e.g. the diminished risk conferred by early 
45 92
castration ' and the increase in risk associated with prolonged
i q ?n 81 
oestrogen administration ' '
The precise role played by oestrogens in the evolution of breast
77
cancer is still the subject of considerable debate but current
thinking is that excessive or prolonged oestrogenic stimulation of
target cells in the breast may render them more susceptible to
carcinogens such as irradiation or chemicals in the diet which then
90 133 155
cause malignant transformation ' ' . Oestrogens would thus be
acting more as a promoter, "setting the scene for carcinogenesis"
than as an inducer or carcinogen. In established breast cancers,
studies on endocrine therapy have clearly indicated the importance
71
of oestrogens m  the maintenance of tumour growth . In terms of
circulating hormones however, there has been little unequivocal
evidence for any consistent abnormality in plasma levels of
87
oestrogen or oestrogen excretion in women with breast cancer .
These findings, however, do not rule out the possibility that the 
breasts of these women have been exposed to abnormal quantities of 
oestrogen. While circulating hormones may be the major source of 
oestrogens or their precursors, local factors within the breast 
may be more important in determining endogenous concentrations of 
oestrogen within the breast and the degree to which breast
109
epithelial cells are exposed to oestrogenic stimuli.
In support of this, the concentrations of most steroid hormones in
breast tissues have been shown to be higher than those in
p l a s m a * ^ ' T h e r e  appears to be no consistent relationship,
however, between plasma and tissue levels. This inconsistency
suggests that variable local factors such as the selective uptake
of steroids from the circulation or local synthesis and metabolism
47
determine tissue concentrations . Such local events are likely to 
be of particular relevance in postmenopausal women, in whom the 
aromatisation c-f androgens within peripheral tissues is the 
principal source of oestrogen*^.
The factors which govern the differential uptake of steroids into
peripheral tissues are largely unknown. With regard to oestrogen
synthesis however, aromatase and 17BHSD activity are critical 
87
control points . Evidence for involvement of these enzymes in
determining local concentrations of hormones comes from the
132
infusion studies of Reed et al . These show that intravenous 
infusion of radiolabeled androstenedione is followed by the 
appearance of labeled oestrone in breast tissues. After infusion
of labeled oestrone, labeled oestradiol is detectable in breast
. , - ^ , , ^ 99,132 tissues '
Within peripheral tissues therefore, there appears to be a 
potential microendocrine system to which hormone sensitive cells 
may be exposed and may respond. The possible contribution of breast 
adipose tissue to such metabolism is affirmed in the present 
studies by the demonstration of both aromatase and 17BHSD activity
110
in all samples of breast adipose tissue examined. In these studies
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and those of others ' ' , enzyme activities varied widely
between individuals and between different body sites. These 
enzymes might therefore contribute to the wide variation in 
oestrogen levels in peripheral tissues and between different parts 
of the breast.
The present studies have shown that aromatase and 17BHSD activity 
both vary widely between the quadrants of cancerous breasts. Since 
it is rarely possible to obtain fresh samples of tissue from 
multiple quadrants of normal or non-cancerous breasts it will be 
difficult to determine whether steroid metabolism also varies 
throughout normal breasts. It is therefore conceivable that 
significant variation in enzyme activity only occurs in those 
breasts which either contain malignant tumours or are likely to 
develop such tumours.
The present studies have shown that enhanced aromatase activity in 
breast adipose tissue is associated with the presence of breast 
cancer, but not with any specific features of the tumours. In 
contrast enhanced 17BHSD activity is not specifically associated 
with breast cancer but is correlated with features of the tumours 
such as size, nodal metastases and response to treatment.
If local aromatase activity determines local tissue concentrations 
of oestrogen then the association of enhanced aromatase activity in 
breast adipose tissue with breast cancer is consistent with the 
hypothesis that increased exposure to oestrogens m y  be an
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important factor in the early evolution of breast cancer. The lack 
of correlation between aromatase activity in adipose tissue and the 
tumour type, stage or oestrogen receptor activity suggests that 
local aromatase activity may be a less significant factor in the 
continued growth and dissemination of most of the tumours, once 
established.
In contrast, levels of 17BHSD activity in breast adipose tissue do 
not differ between cancer patients and patients with benign breast 
disease and levels of activity in breast quadrants do not correlate 
with tumour location implying that activity of this enzyme may not 
be crucial in the early stages of tumour development. The 
correlation between levels of 17BHSD and tumour size, nodal 
metastases and response to treatment suggest that this enzyme may 
be more important in the continued growth and dissemination of 
established tumours.
It remains to be determined whether tumours have a significant
effect on enzyme activities in their surrounding tissues. Tumours
could influence aromatase and 17BHSD activity selectively by
producing factors which increase or inhibit levels of the enzymes
or essential cofactors. Alternatively enzyme activity could be
affected indirectly as a consequence of other effects of tumours on
their surrounding tissues. Tumours are known to produce growth
factors which may modulate enzyme activity in peripheral
t i s s u e s ' ^ T h e s e  include factors which may be produced in a
93
paracrine manner by tumours and preliminary results indicate that
the addition of extracts from breast cancers to cultures of adipose
130
tissue may stimulate oestrogen biosynthesis Some tumours
112
however also produce factors which increase the vascularity of
18
their immediate surroundings (angiogenesis factors) . An increase
in vascularity could also lead to an increase in the numbers of
stromal cells which are thought to be the principal site of
29
aromatase activity . Tumours may also extract nutrients and
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cofactors from their local environment . Such substances may be 
important determinants of local steroid metabolism either as 
essential cofactors for the metabolic pathways or as 
regulators/inhibitors of activity.
The present studies can neither confirm nor refute the possibility 
that tumours influence local metabolism. What can be inferred 
from the results in Chapter 7 however, is that there is no 
consistent trend for either enhancement or inhibition.
It may be possible to determine whether tumours can influence 
metabolism in their surrounding tissues by measuring enzyme 
activities in tissue samples obtained before and after local 
excision or systemic treatment of tumours. Such studies should 
indicate whether tumour excision or regression results in 
significant alteration of local metabolism. Confirmation that any 
changes which occur are due to local effects of the tumour could 
come from parallel in vitro studies where tumour extracts are 
added to cell cultures of adipose tissue.
Even if tumours do influence metabolism in their immediate 
vicinity, the wide variation in activity between different body 
sites and different breast quadrants in some individuals 
indicates that other factors must be involved in enzyme control.
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In view of this local variation in enzyme activities, it is not 
surprising that there is no apparent relationship between enzyme
activity and age, menopausal status, height, weight, obesity , 
parity, age at menarche, age at first full term pregnancy, or 
family history of breast cancer. Such local variation in any one 
individual suggests that there must be local tissue factors which 
influence enzyme activity.
Variable cellularity is unlikely to account for the observed 
variations since the assay results were all corrected for the 
protein concentration of the tissue extracts. This should 
compensate for variations in cellularity.
Although a number of factors have been identified which will modify
103 54
in vitro steroid metabolism (corticosteroids , prolactin ,
a n d r o g e n s ^ c y c l i c  AMP"^, transforming growth factor alpha
epidermal growth factor‘d  and methyl xanthines'^) there is
87
little evidence that any of these factors operate in vivo . 
Unfortunately most of these studies have attempted to correlate 
tissue levels of enzyme activity with circulating levels of these 
factors. There may be little correlation between plasma and 
tissue levels of such substances. Additionally, if these agents do 
influence local enzyme activity then there must be tissue 
differences in levels of the factors to account for the variation 
in activity seen between different body sites in the same 
individual. Further investigation into the control of local 
enzyme activities should concentrate on tissue concentrations of 
factors rather than circulating levels.
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The results in Chapter S suggest a relationship between levels of 
polyunsaturated fatty acids in breast adipose tissue and 17BHSD 
activity. Since fatty acids in adipose tissue reflect the fatty 
acid composition of the diet^'.'^''^ this implies that dietary 
fat could have a direct or indirect influence on 17BHSD. If tissue 
samples can be obtained from different populations with 
substantial differences in dietary fat intake it should be 
possible to determine if diet is an important factor.
Although the results from these studies do not provide conclusive 
proof for the involvement of local metabolism in the evolution and 
progression of breast cancer, the results are consistent with 
potentially significant interactions between the tumour and their 
surrounding tissues. If such interactions do occur, they may be of 
relevance to the management of breast cancer.
It is well recognised that, in the majority of patients, breast
cancer is a systemic disease by the time it is clinically 
59
detectable . Surgical treatment will therefore only cure a small 
proportion of patients. To have any impact on the morbidity and 
mortality from this disease, an effective means of preventing the 
disease must be devised or effective systemic therapy must be 
developed.
The suggestion that local aromatase activity may be important in 
the early evolution of breast cancer assumes that the observed 
levels of aromatase activity have been present for a number of 
months or years. Whether enzyme activity in breast adipose tissue
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remains constant for prolonged time periods has yet to be 
established. It may be possible to measure enzyme activity in 
serial samples of tissue obtained from patients who undergo 
successive breast biopsies. However, given the variation that can 
occur in enzyme activity within one breast quadrant it is likely to 
be extremely difficult to prove whether activity is consistent 
with time.
If enhanced aromatase activity in breast adipose tissue is 
important in the evolution of breast cancer, then the patients with 
benign breast disease who had relatively high activity should be at 
increased risk of developing cancer in the future. These patients 
should therefore be followed closely to determine whether they do 
subsequently develop tumours.
The results in Chapters 3 & 5 suggest that locally enhanced
aromatase activity may be important in the evolution of breast 
cancers. If the factors which control local aromatase can be 
elucidated and are amenable to modification, reduction of activity 
could reduce the incidence of breast cancer or at least delay its 
appearance.
The effectiveness of aromatase inhibitors such as aminoglutethimide
21
in producing tumour regression confirms the importance of 
oestrogen biosynthesis in the continued growth of some breast 
cancers. Whether local activity in breast adipose tissue makes a 
significant contribution to the growth of tumours still remains to 
be confirmed. Nevertheless the responses to aminoglutethimide 
seen in two patients with higher than average aromatase activity
116
suggests that such activity could be important or at least provides 
an indicator of the capacity for peripheral biosynthesis in these 
patients. This explanation is supported by the low aromatase 
activity observed in breast adipose tissue from the patient who 
failed to respond to aminoglutethimide.
It is notable that both patients who responded to aminoglutethimide
had high levels of oestrogen receptor protein in their tumours
whereas the patient who failed to respond had a low oestrogen
receptor protein level. It is well established that oestrogen
receptor positive tumours are more likely to respond to hormonal 
73
manipulation . However, not all oestrogen receptor positive
21
tumours respond to aminoglutethimide , and it is possible that
measurement of both oestrogen receptor protein level and aromatase
activity would enable better selection of patients for such 
therapy.
Response to the anti-oestrogen tamoxifen correlates well with the
73
oestrogen receptor status of breast tumours , although again not 
all oestrogen receptor positive tumours respond. The observation 
of higher levels of aromatase and 17BHSD activity in patients who 
failed to respond to tamoxifen suggests that the local 
microendocrine environment around tumours may be able to overcome 
the effects of tamoxifen. Perhaps such patients would be more 
likely to respond to an aromatase inhibitor rather than an 
anti-oestrogen.
Enhanced 17BHSD activity appears to be associated with tumours 
which have a poor prognosis. The interesting correlation between
117
local levels of 17BHSD and response to therapy suggests that 
measurement of such activity could provide further helpful 
information for determining which patients are likely to respond to 
systemic therapy.
Why reduced activity of this enzyme should predict responsiveness 
of a tumour to chemotherapy is not readily explanable. Perhaps 
locally elevated activity influences tumour metabolism to confer 
resistance to therapy. Further study of the relationship between 
activity of this enzyme and tumour behaviour is needed to clarify 
the position, but if enhanced activity does promote tumour growth 
and resistance to therapy then inhibition or reduction of activity 
might render these tumours susceptible to treatment.
The results from these studies have therefore raised a number of 
questions that now require to be answered in order to clarify the 
role of local steroid metabolism in the natural history of breast 
cancer. The correlations seen in these studies suggest that such 
metabolism may be important in the development and continued growth 
of breast cancers. With greater understanding of the significance 
of local metabolism and the factors which influence activity it may 
be possible to develop more logical and effective systemic therapy 
and even influence the natural history of the disease.
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TABLE A:1 DETAILS OF BREAST CANCER PATIENTS STUDIED.
No. AGE MENOP. PARITY FAMILY HEIGHT WEIGHT QUETLET 
STATUS HISTORY (CM) (Kg) INDEX
1 50 Peri 2+0 - - - -
2 61 Post 2+0 - - - -
3 65 Post 1+0 - 155 62.6 26.1
4 63 Post 2+1 + 153 69.9 29.9
5 54 Post 2+2 - 163 78.9 29.7
6 50 Peri 3+0 - 163 76.4 28.7
7 31 Pre - - - - -
8 45 Pre 0+0 - 165 66.7 24.5
9 76 Post 3+0 - 163 74.4 28.1
10 48 Pre 1+0 - 160 89 34.8
11 31 Pre 1+0 + 155 57.2 23.8
12 39 Pre 2+0 + - - -
13 36 Pre 4+0 - 158 71.2 28.5
14 61 Post 2+0 - 155 66.7 27.8
15 66 Post 8+0 - 173 63.5 21.2
16 45 Pre 2+2 + 165 57.2 21.0
17 64 Post 2+0 - 163 58.1 22.0
18 61 Post 5+0 - 163 68.2 25.8
19 34 Pre 2+0 - 168 68.0 24.2
20 68 Post 2+1 - 160 54.0 21.1
21 58 Post 1+1 - . 163 58.1 22.0
22 46 Pre 3+0 + - - -
23 75 Post 2+0 - 150 50.8 22.6
24 49 Peri 3+1 - 149 54.0 24.5
25 53 Post - - - 63.5 -
26 34 Pre 2+0 + 179 73.5 22.9
27 50 Pre 2+1 - 165 70.0 25.7
28 43 Pre 3+0 - 163 50.8 19.2
29 53 Pre 3+0 + - - -
30 59 Post 1+1 - - - -
31 61 Post 1+0 - 158 65.3 26.3
32 55 Peri 2+0 - - -
33 50 Peri 0+1 - 174 57.6 19.0
34 62 Post 3+0 + 155 59.9 24.9
35 45 Pre 0+0 - 165 53.5 19.7
36 51 Peri 0+0 - 151 47.3 20.8
37 40 Pre 2+0 - 158 74.0 29.8
38 76 Post - - - - -
39 66 Post 0+0 - 160 82.5 32.2
40 63 Post 2+0 + 166 71.5 25.9
41 86 Post - - - - -
42 53 Peri 3+1 - 153 63.5 27.3
43 73 Post 2+0 + - - -
44 58 Peri 0+0 + 165 63.5 23.3
45 39 Pre 0+0 - 158 66.7 26.7
46 50 Pre 4+0 - - - -
47 50 Pre 2+0 - 160 70.0 27.3
48 50 Pre 0+0 - 164 91.4 34.0
49 34 Pre 2+0 + - - -
50 33 Pre 1+2 + 158 57.2 23.1
51 54 Post 0+0 - 154 66.0 27.8
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Table A:2
DETAILS OF PATIENTS WITH EBNIGN BREAST DISEASE.
Number AGE MENOP. PARITY FAMILY DRUG HEIGHT WEIGHT QUETLET 
STATUS HISTORY HIST (CM) (Kg) INDEX
1 45 Pre 1+1 + - 168 64.4 22.8
2 65 Post 3+1 + ■ - 163 70.0 26.5
3 44 Pre 2+1 - - 166 61.7 22.4
4 38 Pre 2+0 - - 158 59.0 23.8
5 31 Pre O-K) - - 160 70.8 27.7
6 32 Pre 1+1 - - 155 57.2 23.8
7 41 Pre 1+0 - - - - -
8 50 Pre 0+0 + - 156 63.5 26.1
9 43 Pre 3+0 - - - - -
10 49 Pre 2+0 - - 158 58.5 23.6
11 33 Pre 0+1 - - 163 56.2 21.3
12 65 Post 1+1 - - 164 53.5 19.9
13 34 Pre - - - - - -
14 49 Pre 3+0 - - 168 60.8 21.6
15 41 Pre 3+0 - - 152 55.3 23.8
16 29 Pre l+O + - 160 57.2 22.3
17 54 Post 1+1 - + 159 63.5 25.3
18 37 Pre 3+1 - - 168 59.4 21.2
19 59 Post 4+0 - -  • - - -
20 45 Pre O+O + - 171 61.7 21.1
21 49 Pre 3+0 - - 167 70.0 25.1
22 36 Pre 2+0 - - 173 70.0 23.4
23 54 Post 3+0 - - 155 57.2 23.8
24 54 Post 2+0 - - - - -
25 46 Pre 140 - - 161 52.2 20.1
26 51 Pre 4+0 + - 171 70.0 23.9
27 39 Pre 2+1 - - - - -
28 53 Peri 2+0 - - - - -
29 49 Peri 1+0 - - 164 67.5 25.1
30 33 Pre 2+1 - - 171 70.0 23.9
31 43 Pre 2+0 - - 173 57.6 19.3
32 31 Pre 3+1 + - - -  ■ -
33 63 Post 2+0 - - - - -
34 47 Pre - - - - - -
35 27 Pre 0+0 -  . - - — —
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Table A;3 CLINICAL DETAILS OF BREAST CANCER PATIENTS STUDIED 
(Tunour size = pathologist’s ueasureaent, figure in brackets s clinical aeasurenent before systeiic therapy)
No. Tucour
stage
Size
(cs)
Location Histology ER level 
(fiol/ig)
Treatsent Node
Status
1 T2No 3.4 + 2 U+LOQ's Inv Ca + In situ Ca 3 * 2 Mx + Cl +ve 10/17
2 T2Nlb 2.0 (4.5) U09 Inv Ca + In situ Ca 82 Ta*. > resp > Mx + Cl +ve 1/8
3 T2No 3.2 LOB Inv Ductal Ca 122 Mx + NS + R/TH +ve 1/6
4 T2No 4.5 6 o'c Inv Ductal Ca 330 Mx + Cl +ve 4/13
5 T2No 3.0 UOB Inv Lobular Ca 0 Mx + Cl +ve 1/13
6 T2Nlb 3.8 12 o’c Inv Kucoid Ca 32 HLE + ANS • +ve 3/5
7 TlNlb 1.3 - . Scirrhous Ca 21 HLE + ANS +ve 1/4
8 Eilat 1.8 * 0.9 LUO RUI L Inv Ca. R Cribrifora L 193 R 70 Bilat HLE -ve
9 T4Nla 8.0 UIB Inv Lobular Ca 25 Tai. no resp > Mx + Cl -ve
10 T3No 2.0 (5.8) L 3 o’c Inv Ductal Ca 20 oox. no resp, CHOP > resp >Mx -ve
11 TINo 1.0 UOB Inv Ductal Ca - Mx + Cl -ve
12 T1N2 1.5 LOS Inv Mucoid Ca 23 HLE ♦ R/TH > Mx +ve
13 ToNo 1.5 L 9 o’c Inv Tubular Ca 92 Mx + Cl -ve
14 T3No 2.8 (5.2) U09 Adenocarcinosa 167 AMS > resp > Mx + Cl -ve
15 TisNo 0.8 L 3 o ’c Intraduct Ca 245 Mx -ve
18 T3No 5.0 UOB Inv Mucoid Ca 93 Oox > resp > Mx + Cl -ve
17 T4No 2.5 (4.0) Central Inv Ductal Ca 129 Tan > resp > Mx + Cl -ve
18 T3No 5.2 (4.0) 12 o’c Inv Lobular Ca 0 CHOP (defaulted) > Mx t Cl -ve
19 T2No 2.8 12 o’c Inv Ductal Ca 2 HLE + ANS -ve
20 ToNla - - Paget’s + In situ Ca 0 Mx + ANS -ve
21 T4Nlb 1.9 Central Inv Ductal Ca 6 Mx + Cl -ve
22 T4No 5.0 UIB Inv Ca 18 CHOP ♦ R/TH > Mx + Cl -ve
23 T2No 4.5 (3.2) L 3 o’c Inv Ductal Ca 0 Tai > progression > Mx + Cl +ve 7/24
24 TINo 1.2 UOB Inv Ca 118 Mx + Cl -ve
25 T2No 3.5 12 o’c Inv Ca 486 Mx ?
28 T3Nlb 0 (10.0) UOB Adenoca. 2 CHOP > Coip. Resp > Mx -ve
27 ToNo 0.8 UOB Inv Ca 23 HLE + ANS -ve
28 T4Nlb 3.0 LIB Inv Ca 0 CHOP > Cosp. Resp > Mx -ve
29 ToMo 1.0 UOB Inv Ca 0 Mx + Cl -ve
30 T2No 0 (4.2) UOQ Inv Ductal Ca 6 AMS >Prog. Dis.)CH0P >CR > Mx -ve
31 T2Nlb 2.0 (4.5) 8 o’c Inv Ductal Ca 0 Tai >Prog, Dis.)CH0P >PR > Mx +ve 7/13
32 ToNo 0 - In situ Ca - Mx + ANS -ve
33 Trecur 5.0 3-fls Inv ca + In situ 0 R/TH for in situ Mx for recur. -ve
34 T2Nlb 3.2 UOB Inv Ductal Ca 789 Mx + Cl +ve 10/23
35 T2Nlb 2.8 8 o’c Inv Tubular Ca 51 Mx + Cl -ve
38 T3Nlb 1.5 (8.2) UIB Inv Ca 19 CHOP > resp > Mx t Cl +ve 2/13
37 T2No 2.5 UOB Inv Ductal Ca 0 Mx + Cl +ve 3/4
38 - 1.2 - Anaplastic Ca - HLE -
39 T2No 2.5 UOB Inv Lobular variant 27 Mx + Cl -ve
40 T3Nlb 5.0 UOB Inv Ductal Ca 7 Mx + Cl (AMS stopped -reaction) +ve 20/29
41 T2Nla 3.8 UOB Inv Mucoid Ca 1072 HLE -
42 T3No 2.0 (5.2) UOB Inv Ductal Ca 227 AM6 > resp > Mx + Cl -ve
43 T2Nlb 1.8 (4.3) 12 o’c Inv Ductal Ca 1151 Tai > resp > Mx + Cl +ve 3/14
44 T4N3 7.0 Central Adenocarcinosa 19 Biopsy > CHOP + R/TH +ve N3
45 T3No 3.0 (5.2) UIB Atypical Medullary Ca 0 Oox )no resp >Chop >resp >Mx +ve 4/11
48 T2No 2.0 LOB Inv Ca 71 Mx + Cl +ve 10/17
47 T4Nla 3.7 UOB Spindle Cell Ca 9 CHOP > no resp > Mx +C1 -ve
48 T2No 2.8 LIB Inv Ca 21 Mx + Cl -ve
49 TINo 0.7 UOB Inv Ca 62 Mx + Cl +ve 2/14
50 T2Nla 2.9 12 o’c Inv Ductal Ca 0 HLE -
51 T2No ■3.8 UIB Inv Ductal Ca 0 Mx + ANS -ve 1 node
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Table A:4
Histological details of benign breast biosies.
Number Location Histology
1 LIQ Fibroadenoma
2 LIQ Fat and fibrous tissue
3 R 3 o'c Benign mammary dysplasia
4 R 3 o'c Fibrocystic disease, fibroadenomatoid nodule
5 UOQ Fibroadenoma
6 6 o'c Benign mammary dysplasia, fibroadenomatoid nodule
7 LOQ Within normal limits (breast reduction)
8 UOQ Benign mammary dysplasia with hyperplasia
9 OUQ Mammary dysplasia, adenosis, sclerosis
10 OUQ Apocrine cysts
11 UOQ Fibrocystic disease
12 UOQ Apocrine cyst, mammary dysplasia
13 LOQ . Pregnancy changes
14 12 o'c Involutional fibrosis
15 LOQ Mammary dysplasia
16 UOQ Within normal limits
17 UIQ Cyst, mammary dysplasia
18 UOQ Dysplasia, peri-ductal mastitis, cysts
19 UOQ Mammary dysplasia
20 Central Cysts, sclerosis
21 UOQ Mammary dysplasia, hyperplasia
22 12 o'c Dysplasia, fibrosis, cysts, hyperplasia
23 UOQ Fibrocystic disease
24 UOQ Fibrocystic disease
25 UIQ Fibroadenoma
26 UIQ Dysplasia, apocrine cysts
27 UIQ Within normal limits
28 L 3 o'c Cysts
29 UOQ Sclerosing adenosis
30 U02 Fibrosis, hyperplasia
31 R 9 o'c Fibrocystic disease
32 UOQ Dysplasia, hyperplasia
33 12 o'c Fat necrosis
34 LIQ, LOQ Normal (breast reduction)
35 LIQ,LOQ Normal (bilateral reduction)
147
Table E:1
AROMATASE ACTIVITY IN ADIPOSE TISSUE FROM BREAST CANCER PATIENTS.
No. ADIPOSE
TISSUE
(GM)
PROTEIN
CONC
(mg/ml)
AROMATASE
%CONV.
AROMATASE 
fmol/mg prot 
/hour
1 0.8 0.9 .033 24.4
2 1.1 1.8 .073 27
3 1.1 1.2 .132 70.4
4 2 1.6 .036 15
5 2 1.2 .09 50
6 2 2.9 .128 29.4
7 1.2 4.7 .362 51.4
8BiI. 0.9/1.2 3.5/2.2 .222/.051 42.3/15.5
9 2.1 1.3 .067 34.9
10 2 1.1 .179 114
11 2 3.1 .145 32.2
12 2 2.0 .033 11
13 2 1.1 .028 16.4
14 2 2.5 .12 32
15 2 6.0 .315 35
16 2 1.7 .163 63.5
17 2 2.7 .075 18.5
18 0.75 1.3 .021 10.8
19 2 1.5 .08 34.2
20 2 1.75 .078 29.9
21 2.1 3.4 .069 13.5
22 2 0.48 .066 78.6
23 2.1 2.2 .078 23.7
24 1 1.5 .091 39.4
25 0.54 3.8 .16 28.0
26 2.2 1.9 .039 14
27 0.9 2.8 .023 5.5
28 2 2.5 .165 44
29 2 1.2 .151 83.8
30 2 2.6 .036 9.2
31 2 0.8 .034 27.0
32 2 1.6 .053 22.1
33 2 3.2 .091 19
34 2 2.3 .055 15.9
35 2 2.5 .045 11.8
36 2 0.6 .08 88.8
37 2 1.8 .038 14.4
38 1.3 4.3 .371 58.1
39 2 1.9 .044 15.4
40 .2 0.7 .024 22.2
41 2 3.1 .08 17.2
42 1.8 0.9 .047 36.4
43 2 1.5 .015 6.7
44 0.7 2.4 .090 25
45 2 3.2 .272 56.7
46 1.6 1.4 .046 21.9
47 2 4.7 .122 17.3
48 1 0.7 .038 36.2
49 2 2.2 .067 20.3
50 2 1.4 .106 50.5
51 2 1.5 .053 41.3
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Table B:2
Adipose tissue aromatase activity in women with benign breast disease
No. ADIPOSE
TISSUE
(GM)
PROTEIN
CONC
(mg/ml)
AROMATASE
%CONV.
AROMATASE 
fmol/mg prot 
/hour
1 0.53 1.93 .057 19.8
2 1.75 1.1 .095 58.6
3 0.83 2.3 .126 41
4 0.6 4.7 .054 7.7
5 1.9 1.7 .061 26.3
6 1 2.7 .062 15.3
7 2 2.5 .055 14.7
8 0.7 3.2 .067 14.1
9 2.2 4.4 .055 8.3
10 0.9 3.4 .055 10.8
11 1.5 3.1 .101 23.9
12 2 2.8 .038 9.0
13 1 2.4 .074 20.6
14 0.7 1.4 .057 27.5
15 0.6 1.4 .027 12.9
16 2 2.5 .032 8.5
17 2.2 4.8 .052 7.2
18 2.2 3.8 .058 10.2
19 2 1.5 .098 43.6
20 0.6 3.6 .095 19.4
21 1.2 2.9 .113 27.5
22 0.7 3.8 .027 4.7
23 0.5 2.1 .014 4.4
24 1.5 2.7 .07 17.3
25 2 1.2 .028 15.6
26 1 5.0 .083 11.1
27 2 2.3 .024 7.0
28 0.5 3.1 .029 6.2
29 2.2 3.2 .050 10.4
30 1.5 1.5 .053 22.9
31 1.1 1.9 .069 24.5
32 0.7 3.1 .044 10.3
33 2 1.3 .006 3.1
34 2 2.6 .022 5.6
35Bil 2/2 3.3/4.3 .046/.076 9.3/11.8
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Table
17BHSE1
E: 3.
ACTIVITY IN BREAST ADIFOSE TISSUE FROM
17BOHSD 
pmol/mg pi 
/hour
No.
BREAST CANCER PATIENTS.
ADIPOSE PROTEIN 
TISSUE CONC 
(GM) (mg/ml)
17BOHSD
%CONV
1 1.1 1.7 9.08 3.5
3 1.1 1.2 3.93 2.1
4 2 1.2 3.5 1.9
6 2 2.2 13.8 4.2
8Bil 0.9/1.2 3.5/2.2 7.4/4.7 1.4/1.
9 2.1 1.3 7.0 3.6
10 2 1.1 1.4 0.9
11 2 3.1 0.31 .07
12 2 2.0 4.34 1.4
13 2 1.1 2.3 0.9
14 2 2.5 1.4 0.5
15 2 3.7 . 3.0 0.5
16 2 1.7 2.1 0.8
17 2 2.7 4.1 1.0
18 0.75 1.3 1.8 0.9
19 2 1.5 2.9 1.3
20 2 1.75 5.95 1.9
22 2 0.48 38 52.8
23 2.1 2.2 13.5 4.1
24 1 1.5 0.07 .03
25 0.54 3.8 12.9 2.3
26 2.2 1.9 0.18 0.06
27 0.9 2.8 1.2 0.28
28 2 2.5 3.0 0.8
29 2 1.2 2.9 1.6
30 2 2.6 1.2 0.3
31 2 0.8 1.1 0.8
33 2 2.4 0.16 .04
34 2 2.3 6.4 1.85
35 2 2.5 1.4 0.4
36 2 0.6 10 11.11
37 2 1.8 8.9 3.5
39 2 1.9 1.6 0.3
40 2 0.7 3.4 3.3
41 2 3.1 12.2 2.6
42 1.8 0.9 1.7 1.3
43 2 1.5 1.0 0.6
44 0.7 2.4 4.6 1.3
45 2 3.2 9.0 1.9
46 1.6 1.4 16.4 7.8
47 2 4.7 19.7 6.55
48 1 0.7 2.4 2.3
49 2 2.2 0.86 0.3
50 2 1.4 11.8 5.6
51 2 1.5 9.2 4.1
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Table B:4
17BHSD activity in breast adipose tissue from 
women with benign breast conditions
No. ADIPOSE PROTEIN
TISSUE CONC
(GM) (mg/ml)
1 0.53 1.93
2 1.75 1.1
3 0.83 2.3
4 0.6 4.7
5 1.9 1.7
6 1 2.7
8 0.7 3.2
9 2.2 4.4
10 0.9 3.4
11 1.5 3.1
12 2 2.8
13 1 2.4
14 0.7 1.4
15 0.6 1.4
16 2 2.5
17 2.2 4.8
18 2.2 3.8
19 2 1.5
20 0.6 3.6
21 1.2 2.9
22 0.7 3.8
23 0.5 2 .L
24 1.5 2.7
25 2 1.2
26 1 5.0
27 2 2.3
28 0.5 3.1
29 2.2 3.2
30 1.5 1.5
31 1.1 1.9
32 0.7 3.1
33 2 1.3
17BHSD 17BHSD
%CONV pmol/mg prot
/hour
I.33 0.4
5.77 3.6
4.4 1.3
0.9 0.1
2.1 0.7
2.0 0.5
0.7 0.1
5.1 0.8
0.9 0.2
II.7 2.5
14.9 3.5
7.1 2.0
4.8 2.3
1.4 0.7
6.3 1.7
5.2 0.7
8.3 1.5
2.7 0.6
6.7 1.2
15.8 3.5
1.7 0.3
0.9 0.3
6.1 1.5
0.8 0.4
1.8 0.2
17.4 5.1
2.1 0.4
7.1 1.5
3.7 1.6
4.2 1.5
0.7 0.1
20.1 10.3
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Table B:5.
Aromatase activity in adipose tissue from the four quadrants
No. QUAD ADIPOSE
TISSUE
(GM)
of individual
PPOTEIN
CONC
(mg/ml)
breasts.
AROMATASE
%CONV.
a r om a t a: 
fmol/mg ] 
/hour
4 UOQ 2.1 2.1 .030 9.5
UIQ 2 1.5 .014 6.2
LIQ* 2 1.2 .019 10.5
LOQ* 2 1.6 .036 15
9 UOQ 2.1 4.3 .079 12.3
UIQ* 2.1 1.3 .067 34.9
LIQ 2.1 2.1 .023 7.7
LOQ 2.1 2.8 .030 7.1
11 UOQ* 2 3.1 .145 32.2
UIQ 2 2.7 .101 24.9
LIQ 2 2.3 .079 22.9
LOQ 2 2.8 .115 27.4
14 UOQ* 2 2.5 .12 32
UIQ 2 1.3 .046 23.6
LIQ 2 1.92 .075 26.0
LOQ 2 2.2 .079 23.9
15 UOQ* 1.3 2.7 .099 17.8
UIQ 2 4.2 .066 10.5
LIQ 2 5.6 .126 15
LOQ* 2 6.0 .315 35
18 UOQ* 1.2 1.3 .014 7.2
UIQ* 0.75 1.3 .021 10.8
LIQ 0.5 3.7 .020 3.6
LOQ 0.9 1.5 .008 3.6
23 OUQ* 2.1 2.2 .078 23.7
UIQ 2 2.1 .033 10.5
LIQ 2.1 1.5 .011 4.9
LOQ 2 2.2 .034 10.3
26 UOQ* 2.2 1.9 .039 14
UIQ 2.2 3.0 .055 12.2
LIQ 2.2 1.3 .011 5.6
LOQ 2.2 1-4 .015 7.1
33 OUQ* 2 1.9 .038 13.1
UIQ* 2 2.4 .050 14
LIQ 2 3.1 .046 10
LOQ* 2 3.2 .091 19
34 . UOQ* 2 2.3 .055 15.9
UIQ 2 1.7 .021 8.2
LIQ 2 1.9 .031 10.9
LOQ 2 1.8 .014 5.2
39 - OUQ* 2 1.9 .044 15.4
• UIQ 1.3 4.4 .064 9.7
LIQ 2 4.1 .076 12.3
LOQ 1.2 3.6 .068 12.5
47 UOQ* 2 4.7 .122 17.3
UIQ 2.1 2.9 .027 6.2
LIQ 2.1 2.9 .051 11.7
LOQ 2 2.3 .047 14
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Table B:6.
17BHSD activity ir. adipose tissue from breast quadrants.
NO. QUAD ADIPOSE 
TISSUE 
(GM)
PROTEIN
CONC
(mg/ml)
17BHSD
%CONV
17BHSD 
pmol/mg prot 
/hour
4 UOQ 2.1 2.1 5.4 1.7
UIQ 2 1.5 3.4 1.5
LIQ* 2 1.2 3.5 1.9
LOQ* 2 1.6 3.8 1.6
9 UOQ 2.1 4.3 4.7 0.7
UIQ* 2.1 1.3 7.0 3.6
LIQ 2.1 2.1 5.7 1.9
LDQ 2.1 2.8 4.9 1.2
11 UOQ* 2 3.1 0.31 0.067
UIQ 2 2.7 0.28 0.069
LIQ 2 2.3 0.19 0.055
LOQ 2 2.8 0.28 0.067
14 UOQ* 2 2.5 1.4 0.5
UIQ 2 1.3 1.4 0.47
LIQ 2 1.92 1.7 0.57
LOQ 2 2.2 2.8 0.9
15 UOQ* 1.3 2.7 3.0 0.5
UIQ 2 4.2 3.1 0.5
LIQ 2 5.6 3.6 0.4
LOQ* 2 6.0 14.9 1.7
18 UOQ* 1.2 1.3 1.7 0.87
UIQ* 0.75 1.3 1.8 0.9
LIQ 0.5 3.7 3.1 0.56
LOQ 0.9 1.5 1.6 0.7
23 OUQ* 2.1 2.2 13.5 4.10
UIQ 2 2.1 18.3 5.8
LIQ 2.1 1.5 9.3 4.13
LOQ 2 2.2 13.8 4.18
26 UOQ* 2.2 1.9 0.18 0.06
UIQ 2.2 3.0 0.14 0.03
LIQ 2.2 1.3 0.13 0.07
LOQ 2.2 1.4 0.17 0.08
33 OUQ* 2 1.9 0.19 0.065
UIQ* 2 2.4 0.16 0.044
LIQ 2 3.1 0.18 0.039
LOQ* 2 3.2 0.22 0.046
34 UOQ* 2 2.3 6.4 1.85
UIQ 2 1.7 5.6 2.2
LIQ 2 1.9 5.8 2.0
LOQ 2 1.8 10.0 3.7
39 OUQ* 2 1.9 1.6 0.3
UIQ 1.3 4.4 2.4 0.36
LIQ 2 4.1 2.3 0.37
LOQ 1.2 3.6 2.1 0.39
47 UOQ* 2 4.7 19.7 6.55
UIQ 2.1 2.9 7.3 2.3
LIQ 2.1 2.9 13.5 4.3
LOO 2 2.3 3.7 1.2
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